



Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems

Hedegaard, Chris Juul; Heegaard, Peter M. H.

Published in:
Veterinary Immunology and Immunopathology

Link to article, DOI:
[10.1016/j.vetimm.2016.04.007](https://doi.org/10.1016/j.vetimm.2016.04.007)

Publication date:
2016

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Hedegaard, C. J., & Heegaard, P. M. H. (2016). Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems. *Veterinary Immunology and Immunopathology*, 174, 50-63. <https://doi.org/10.1016/j.vetimm.2016.04.007>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **Veterinary Immunology and Immunopathology**

2 Volume 174, June 2016, Pages 50–63

3

4 Review paper

5 **Passive immunisation, an old idea revisited: Basic principles and**
6 **application to modern animal production systems**

7 Chris J. Hedegaard, Peter M.H. Heegaard

8 National Veterinary Institute, Technical University of Denmark, Section for Immunology
9 and Vaccinology, The innate immunology Group, Denmark

10 Received 16 December 2015, Revised 11 April 2016, Accepted 13 April 2016, Available
11 online 26 April 2016

12

13 **Abstract**

14 Immunisation by administration of antibodies (immunoglobulins) has been known for
15 more than one hundred years as a very efficient means of obtaining immediate, short-
16 lived protection against infection and/or against the disease-causing effects of toxins
17 from microbial pathogens and from other sources. Thus, due to its rapid action, passive
18 immunisation is often used to treat disease caused by infection and/or toxin exposure.
19 However immunoglobulins may also be administered prior to exposure to infection
20 and/or toxin, although they will not provide long-lasting protection as is seen with active

21 immunisation (vaccination) in which an immunological memory is established by
22 controlled exposure of the host to the pathogen in question. With multi-factorial
23 infectious diseases in production animals, especially those that have proven hard to
24 control by vaccination, the potential of passive immunisation remains big. This review
25 highlights a number of examples on the use of passive immunisation for the control of
26 infectious disease in the modern production of a range of animals, including pigs, cattle,
27 sheep, goat, poultry and fish. Special emphasis is given on the enablement of passive
28 immunisation strategies in these production systems through low cost and ease of use
29 as well as on the sources, composition and purity of immunoglobulin preparations used
30 and their benefits as compared to current measures, including vaccination (also
31 comprising maternal vaccination), antibiotics and feed additives such as spray-dried
32 plasma. It is concluded that provided highly efficient, relatively low-price
33 immunoglobulin products are available, passive immunisation has a clear role in the
34 modern animal production sector as a means of controlling infectious diseases,
35 importantly with a very low risk of causing development of bacterial resistance, thus
36 constituting a real and widely applicable alternative to antibiotics.

37

38 **Abbreviations**

39 ETEC, enterotoxigenic Escherichia coli; EPEC, enteropathogenic Escherichia coli; FMD,
40 foot and mouth disease; FPT, failure of passive transfer; IVIG, intravenous
41 immunoglobulin; PCV2, porcine circovirus type 2; PEDV, porcine epidemic diarrhoea
42 virus; PWD, post-weaning diarrhoea; SDP, spray-dried plasma

43 **Keywords**

44 Passive immunisation; Maternal immunity; Lactogenic immunity; Immunoglobulins;
45 Production animals; Agammaglobulinemic; Gastro intestinal tract; Postweaning
46 diarrhoea; Failure of passive transfer; Colostrum; enterotoxigenic Escherichia coli;
47 Porcine circo virus type 2; Spray-dried plasma

48 **1. Introduction**

49 Passive immunisation, i.e. the administration of antibodies (immunoglobulins) in order
50 to protect against infection and/or disease was first demonstrated experimentally more
51 than 100 years ago by, among others Albert Calmette who protected rabbits against a
52 lethal dose of cobra venom by giving antibodies in the form of antiserum parenterally
53 prior to or within one hour of venom injection (Calmette, 1896). Since its discovery the
54 principle of passive immunisation has been used extensively for treating and preventing
55 diseases in animals and humans (Baxter, 2007, Eibl, 2008 and Hsu and Safdar, 2011),
56 supplementing active immunisation, i.e. vaccination. In contrast to vaccination,
57 administration of immunoglobulin establishes instant immunity and provides short term
58 protection with no induction of immunological memory. For most applications it works
59 across species, i.e. the species origin of the immunoglobulins is less important. Also, in
60 contrast to active immunisation, existing antibodies (e.g. maternally derived) do not
61 interfere with passive immunity provided by administration of immunoglobulins. The
62 main drawbacks of passive immunisation include the risk of adverse reactions to the
63 administered immunoglobulins, especially if given repeatedly and if given as a non-
64 purified preparation.

65 In animal production systems both active and passive immunisation may be considered
66 alternatives to the use of antibiotics, as none of these normally lead to the development
67 of antibiotics resistance problems or to microbial resistance generally; the exception

68 being creation of escape mutants of viruses with high mutation rates. Thus in the
69 present era of increasing problems with antibiotics resistance development (see below),
70 immunisation methods are becoming attractive for wider application to the treatment
71 and prevention of infectious diseases in production animals. However, a main
72 prerequisite for this use is their cost-effectiveness compared to antibiotics which are
73 presently used very extensively as inexpensive and highly efficient means for reducing
74 animal morbidity and mortality, boosting food conversion, animal welfare and growth
75 (De Briyne et al., 2014 and Garcia-Migura et al., 2014). The possible role of the wide use
76 of antibiotics in the surge of microbial antibiotics resistance experienced during the last
77 few decades is discussed in (Barton, 2000, Bester and Essack, 2012, Garcia et al., 2011,
78 Hong et al., 2007 and Mendez Arancibia et al., 2009). The situation threatens to become
79 a major problem for treating infectious diseases in humans (Barton, 2000 and
80 Fairbrother et al., 2005) and, generally, increased human mortality associated with
81 antibiotics resistant bacteria has been predicted (CDC, 2013, de Kraker et al., 2011,
82 ECDC/EMA, 2009 and WHO, 2012).

83

84 Enteric infections are often encountered in animal production and constitute the main
85 target for antibiotics intervention; this group of infections constitute a specific challenge
86 for traditional active immunisation methods as efficient mucosal immunity is generally
87 not easily achieved by vaccination (Rhee et al., 2012), and as vaccines against enteric
88 infections often need to be directed against a broad spectrum of bacterial and possibly
89 also viral pathogens in order to provide complete protection against disease (Qadri et
90 al., 2013). However, as discussed extensively below, passive immunisation in the form of
91 orally administered immunoglobulins represents an easily applied and affordable

92 solution for immediate treatment of and short term protection against enteral
93 infections, having the potential for being a real alternative to the use of antibiotics in the
94 animal production, especially for intervention at specific time periods in the production
95 in which animals are particularly exposed to enteric infectious disease such as at birth
96 and at weaning. In addition, passive immunisation can be and are currently used for
97 other types of infectious diseases in production animals using a range of different
98 administration routes (see below).

99

100 **2. Natural and passive immunity: maternal antibodies and lactogenic immunity**

101 **2.1. Natural passive immunity**

102 Passive immunisation is widely used in Nature to protect offspring against disease at
103 birth and during lactation (mammals) or in ovo (birds and fish). This is achieved by
104 transfer of immunoglobulins from mother to progeny, in some species transported by
105 blood through the placenta or yolk sack at the foetal stage and during lactation in
106 mammals by the oral route through ingestion of colostrum and/or milk (oro-gastric or
107 lactogenic immunity) (Hurley and Theil, 2011 and Palmeira et al., 2012).

108 Evolutionarily, transfer of maternal immunoglobulins to offspring can be traced as far
109 back as 450 million years ago, being found in primitive fish like the nurse shark (Haines
110 et al., 2005). In some mammals, including primates and rabbits, the foetus obtains
111 immunoglobulin (Ig) G over the placenta (Hurley and Theil, 2011 and Palmeira et al.,
112 2012) and the new-born is thus born with circulating mammalian IgG, persisting in the
113 systemic circulation for some months after birth. The half-life of circulatory IgG in man is
114 around 3 weeks (see below, Table 1), thus it has been observed that maternal antibodies

are detectable in children 2–3 months after birth as seen in a study on circulating maternal anti-*Neisseria meningitidis* IgG (Shahid et al., 2002). This is supplemented during lactation by the intake of maternal IgA-type immunoglobulin through the milk building up local immunity in the gastrointestinal tract (Malek, 2013). In other mammals such as pigs and ruminants, placental immunoglobulin transfer does not take place and consequently the neonate is born agammaglobulinemic (without immunoglobulin), having neither received maternal immunoglobulin nor initiated their own production of immunoglobulins. Instead, these species are born with an ‘open gut’ allowing Fc-receptor-mediated immunoglobulin transfer from the gut to the circulation for the first approximately 24 h after birth assuring the very quick establishment of the necessary circulating levels of maternal immunoglobulins through ingestion of colostrum which in these species contains high concentrations of IgG (Cervenak and Kacskovics, 2009). Notably in pigs, colostral IgG concentrations decrease by 80% within 24 h of parturition (Foisnet et al., 2010). A variation of this is seen in rodents and some other species, including mink, where the neonate is born with a certain level of circulating maternal immunoglobulins and has its gut open for transfer of immunoglobulin from the milk for 2–3 weeks postnatally (Brambell, 1966 and Kim et al., 2009). In chickens, the pre-hatching chick receives maternal immunoglobulin through the yolk sac of the egg and therefore is ‘born’ with maternal immunoglobulin at hatching (Kowalczyk et al., 1985).

Once maternal circulatory IgG is no longer replenished, i.e. after parturition and gut closure the half-life of IgG is around 2–3 weeks in larger mammals (Table 1). In small mammals such as mice the half-life of IgG in the circulation is only a few days which is also the case for immunoglobulin Y (IgY) in birds, and tetrameric IgM in fish (Table 1). Other circulatory immunoglobulins, such IgA, IgD, IgE, and IgM have much shorter half-

139 lives than IgG in humans (Vidarsson et al., 2014), pigs (Curtis and Bourne, 1973) and
140 mice (Fahey and Sell, 1965 and Hirano et al., 1983).

141 Immunoglobulins of human milk and colostrum are largely dimeric IgA (Hurley and Theil,
142 2011) produced by the mucosal lymphoid tissue of the breastfeeding mother
143 (Brandtzaeg, 2010) and, as they are not taken up by the intestine (Brandtzaeg, 2010),
144 provide oro-gastric protection only, whereas colostrum from lactating cows and pigs
145 contains a very high content of IgG originating from stimulated B cells/plasma cells of
146 the dam's blood (Larson et al., 1980 and Quigley, 2002) destined for the circulation of
147 the offspring by intestinal uptake perinatally as detailed above.

148 Colostrum also contains leukocytes and antimicrobial proteins (such as Complement C3,
149 lactoferrin, lactoperoxidase, and lysozyme) (Hernandez-Castellano et al., 2015 and
150 Smolenski et al., 2007). Colostral leukocytes are believed to participate in oro-gastric
151 protection together with maternal immunoglobulins (Goldman, 1977 and Morgan et al.,
152 1984), and may enter circulation by intestinal absorption promoting neonatal cellular
153 immunity (Liebler-Tenorio et al., 2002, Salmon et al., 2009 and Tuboly and Bernath,
154 2002).

155 Thus, the principle of passive immunisation by transfer of immunoglobulin is well-known
156 in Nature, both for providing oro-gastric immunity against pathogens during the suckling
157 period (lactogenic immunity based on locally residing immunoglobulins from mother's
158 milk and colostrum), and for providing systemic immunity either by foetal transfer
159 (primates) or by perinatal transfer from the colostrum (pigs, ruminants) and milk
160 (rodents and mink), boosting circulating (IgG-like) immunoglobulin levels before onset of
161 the offspring's own immunoglobulin production.

162

163 2.2. Maternal immunisation to increase off-spring passive immunity

164 The natural transfer of maternal immunity has to some extent been exploited to
165 passively immunize offspring by maternal vaccination. For example, prevention of
166 rotavirus infection, which has a great economic impact in husbandry, especially in cattle-
167 and hog production (Saif and Fernandez, 1996), can be obtained by vaccination of
168 lactating cows against rotavirus resulting in subsequent passive immunity-mediated
169 protection in calves receiving colostrum from the vaccinated cows (Le Rousic et al.,
170 2000, Parreno et al., 2004, Saif and Fernandez, 1996 and Tsunemitsu et al., 1989).
171 Similar observations on lactogenic immunity against rotavirus have been made in pigs
172 (Fu et al., 1990). Likewise, neonate offspring from cows vaccinated with an extract of
173 ETEC (enterotoxigenic *Escherichia coli*) O101:K99 were protected against enteral
174 colibacilliosis (otherwise causing fatal diarrhoea in calves) (Nagy, 1980), and moreover
175 protection against *Salmonella Typhimurium* was obtained by vaccinating dams with
176 formalin-fixed *Salmonella Typhimurium* (Jones et al., 1988) after experimental
177 challenge. Furthermore, a combined vaccination of pregnant cows against *E. coli* and
178 rotavirus is an efficient means of protecting against calf diarrhoea (Combs et al., 1993
179 and Snodgrass et al., 1982). Lactogenic immunity against larval cestodes and
180 metacestodes has also been reported (Larsh, 1942 and Lloyd and Soulsby, 1976). For
181 lactogenic immunity to be efficient, it was show that the vaccine had to be administered
182 to the dams at least two weeks before parturition to allow enough time for adequate
183 antibody titres to develop (Haggard et al., 1982). Oro-gastric immunity has been
184 demonstrated in piglets provided with milk from immuno-competent lactating sows as
185 seen by a decrease in faecal shedding of haemolytic *E. coli* by suckling piglets whereas
186 milk from non-immune sources did not reduce shedding (Deprez et al., 1986). Passive
187 immunisation of piglets by immunisation of the pregnant sow a few weeks before

188 parturition has also been demonstrated in a porcine epidemic diarrhoea virus (PEDV)
189 infection model; intramuscular injection of the sow with live attenuated PEDV 2–4
190 weeks before farrowing conferred significant protection to the suckling piglets (Kweon
191 et al., 1999).

192 One important point to bear in mind is that maternal antibodies present in the offspring
193 may potentially interfere with active immunisation (i.e. vaccination) of the offspring by
194 binding to the vaccination antigen(s) and thereby inhibiting them from activating the
195 offspring's immune system. This becomes critical in situations in which vulnerability to
196 infection is present at the same time as colostrum derived antibodies. As an example
197 anti-hepatitis A virus specific antibodies passed on from mother to infant persists for up
198 to 6 months in the new-born preventing vaccination of infants against hepatitis A virus
199 in this period (Vidor, 2007). Also, vaccinating pregnant sows at the right time before
200 farrowing can protect piglets against Foot-and Mouth Disease (FMD) through colostrum
201 derived maternal antibodies (Francis and Black, 1984a and Francis and Black, 1984b) for
202 a limited period of time after birth. However maternal antibodies are capable of
203 inhibiting subsequent active immunisation against FMD in the piglets even at around 8
204 weeks after parturition (Kitching and Salt, 1995). Interfering maternal antibodies have
205 also been observed in poultry, inhibiting vaccination against H5N2 influenza virus
206 (Forrest et al., 2013). As dealt with in the rest of the review, other ways of creating
207 antibody based passive immunity is to administer immunoglobulins orally or by
208 injection, thereby controlling the location and the timing of immunoglobulins more
209 precisely.

210

211 **3. Protection and prevention of infection by passive immunisation of humans**

212 A wide range of immunoglobulin products are currently commercially available for
213 treating or preventing various infections and/or toxin-mediated diseases in humans by
214 parenteral administration, including those listed in Table 2. In addition to maternal
215 vaccination sometimes being useful for protecting the new-born by maternal antibody
216 transfer as mentioned above a number of other passive immunisation strategies have
217 been studied in humans and/or in models of human diseases (Keller and Stiehm, 2000
218 and Zeitlin et al., 1999). This includes parenteral administration of immunoglobulin
219 preparations for treating and/or preventing influenza (Mancini et al., 2011), plague
220 caused by *Yersinia pestis* (Froude et al., 2011) and viral haemorrhagic fevers (such as
221 Ebola (Qiu et al., 2014)). Passive immunisation is also used to protect against a number
222 of toxins from venomous animals, and bioterror-related toxins (reviewed in (Froude et
223 al., 2011)).

224 Oral intake of immunoglobulins for oro-gastric protection against enteric infections is
225 well-known in Nature (see above) and this principle has been applied in human medicine
226 for preventing and treating enteric infectious disease. For example, healthy human
227 volunteers given orally colostrum from cows immunised with several *E. coli* serotypes,
228 fimbria types, *E. coli* heat-labile enterotoxin, and cholera toxin, were all protected
229 against diarrhoea when challenged with *E. coli* O78:H11 in contrast to 9/10 in a control
230 group receiving non-immune bovine colostrum (Tacket et al., 1988). Although bovine
231 milk contains some antibody reactivity against human rotavirus (Yolken et al., 1985) it
232 appears that hyper-immune colostrum from immunised cows is needed to alleviate
233 disease symptoms in children with rotavirus-induced diarrhoea (Ylitalo et al., 1998).
234 Moreover children diagnosed with rotavirus induced diarrhoea treated with hyper-
235 immune colostrum were less dehydrated and showed better virus clearance than when
236 receiving non-hyper-immune colostrum (Davidson et al., 1989 and Sarker et al., 1998).

237 Likewise, HIV patients with *Cryptosporidium parvum* induced diarrhoea were
238 successfully treated by oral administration of a bovine immunoglobulin concentrate
239 derived from *C. parvum* immunised cows (Greenberg and Cello, 1996). A general
240 concern associated with oral administration of immunoglobulins is that the protein
241 degrading conditions of the gut may greatly reduce immunoglobulin activity (Jasion and
242 Burnett, 2015). Indeed, the combined action of low pH and proteolytic enzymes has
243 been shown to reduce the virus-neutralising capacity of bovine colostrum
244 immunoglobulins (Petschow and Talbott, 1994). Human milk IgA and IgM appear to be
245 more resistant to proteolysis than IgG as shown e.g. by mass spectrometry (Zhang et al.,
246 2014). The general observation in humans is that up to 25% of IgG passing through the
247 digestive system can afterwards be found intact in stool (Jasion and Burnett, 2015). In
248 study in rabbits that were fed bovine immunoglobulins from Cholera enterotoxin-
249 immunised cows, and the rabbit cecal extract was shown to possess Cholera enterotoxin
250 neutralization ability in vivo (McClead and Gregory, 1984). Intact, non-denatured IgG
251 could also be found throughout the digestive system after oral administration of ovine
252 IgG to rats (Balan et al., 2014). It should be noted that colostrum contains protease
253 inhibitors, such as inter-alpha-trypsin inhibitor and alpha-1-antichymotrypsin (Danielsen
254 et al., 2011 and Hernandez-Castellano et al., 2015). Also, the pH in the stomach of
255 weaned piglets is never below 2.5 (Snoeck et al., 2004), both of which contribute to
256 sustain immunoglobulin stability upon oral administration

257

258 **4. Passive immunisation of production animals**

259 **4.1. Pigs**

260 A number of difficult to control diseases with infectious aetiology, such as post weaning
261 diarrhoea (PWD), porcine epidemic diarrhoea, porcine circovirus associated diseases,
262 and new neonatal porcine diarrhoea syndrome, occur with a significant incidence in the
263 modern pig production worldwide. Vaccines are available for some of them including a
264 number of viral infections (see below) and others can be prevented or treated by
265 antibiotics, but products for passive immunisation of pigs are quite limited in type and
266 scope (see Table 4), and none are currently available for protecting against these
267 diseases.

268 Most pigs in North America and Europe are presently infected with type 2 porcine
269 circovirus (PCV2)(Madec et al., 2008). Several PCV2-vaccines have been developed after
270 the millennium and have proved useful for controlling PCV2-associated diseases (Chae,
271 2012 and Kristensen et al., 2011). As it is costly and time-consuming to vaccinate all
272 piglets against PCV2 it would be highly preferable to vaccinate the sows only, i.e. to rely
273 on passive immunity for protection of the piglets. It has indeed been observed that
274 clinical signs of PCV2-infection are reduced in the offspring of vaccinated sows provided
275 maternal anti-PCV2 titres are adequate (Fort et al., 2008, McKeown et al., 2005 and
276 Opriessnig et al., 2008), and one commercial sow vaccine has been reported to provide
277 passive immunity in piglets by maternally derived antibodies and lymphocytes (Table 3)
278 (Fort et al., 2008, Fort et al., 2009 and Oh et al., 2012). On the other hand, vertical
279 transmission of PCV2 may occur even in the face of maternal vaccination (i.e. PCV2
280 transmitting through milk) (Dvorak et al., 2013, Gerber et al., 2012, Madson et al., 2009
281 and Shibata et al., 2006), and maternal antibodies can potentially impede the piglet
282 immune response to vaccination as seen in a study on oral vaccine against F4+ ETEC
283 (Snoeck et al., 2003). Collectively, it does appear that neither active immunisation nor

284 lactogenic passive immunisation provided by maternal antibody transfer can prevent
285 PCV2 infection even though disease signs are reduced.

286 Infection with diarrhoeagenic ETEC affects newly weaned piglets causing post weaning
287 diarrhoea (PWD), which is a very widespread problem in modern pig production systems
288 (Fleckenstein et al., 2010, Gyles, 1994 and Hong et al., 2006). The key step in the
289 pathogenesis of PWD is the fimbria-receptor interaction necessary for the colonisation
290 by ETEC of the small intestine (Gaastra and Svennerholm, 1996 and Zhou et al., 2013).
291 An orally provided F4 fimbria subunit vaccine was shown to be able to induce protection
292 against F4 positive ETEC in an experimental model of PWD (Van den Broeck et al., 1999a
293 and Van den Broeck et al., 1999b). One commercial vaccine (Coliprotec®) for oral use
294 against PWD, containing live avirulent E. coli F4+ strain, has been marketed in Canada
295 for some years (Melkebeek et al., 2013) and was approved for the European market in
296 2015 as well (EMA, 2015). Efficacy data for this vaccine do not seem to be available.
297 However, the use of oral vaccines based on live bacteria for oro-gastric protection has
298 several limitations, including (1) in nursing piglets interfering lactogenic maternal
299 antibodies may inhibit induction of active immunity as intestinal colonisation by the
300 bacteria is inhibited, (2) oral vaccination only works fully if the weaners are able to
301 mount a full immune response, which is not the case at four weeks of age (Levast et al.,
302 2014), (3) the vaccine cannot be provided in combination with antibiotics as these will
303 kill the live bacteria of the vaccine, and (4) if the vaccine only provides protection against
304 specific antigens (e.g. F4 fimbriae) it will not work in geographical regions where other
305 bacterial strains prevail (e.g. E. coli F18+). However, passive immunisation was shown to
306 protect new-born piglets against otherwise fatal diarrhoea caused by ETEC F4+ by oral
307 administration of a combination of several monoclonal antibodies targeting different F4
308 fimbria subunits (25 mg/ml in ascites fluid) (Foged et al., 1986). Notably, one oral dose

(1 ml) of this monoclonal antibody mixture provided 1 h prior to challenge did not provide protection, however combining administration before challenge with administration at 8, 24 and 32 h after challenge provided complete protection against mortality and disease. Ten days of feeding genetically engineered Arabidopsis plant seeds expressing F4-specific llama-derived immunoglobulin was reported by Viridi et al., 2013 to reduce excretion of F4 positive ETEC (experimental challenge at day 6) and to increase the weight gain in pigs (Viridi et al., 2013). Antibodies from hens' eggs (also known as IgY, see below) have also been investigated for their ability to provide passive protection against enteric infections in pigs, however results have been ambiguous (see below). Thus, a study on E. coli F18+-specific IgY-containing egg yolk fed to weaning pigs that had been challenged with virulent E. coli F18+ showed that growth was significantly improved, and both diarrhoea incidence and E. coli colonisation reduced compared to the control groups (Yokoyama et al., 1997). This finding was confirmed in an independent study feeding either egg powder or eggs from fimbria F18-immunised hens to weaning piglets which led to significantly less shedding of the E. coli F18+ challenge strain, reduced incidence of diarrhoea, and reduced mortality compared to weaner piglets fed eggs or egg powder from non-immunised hens (Imberechts et al., 1997). Also, a feed supplement of egg yolk powder from eggs of E. coli F4+-immunised hens decreased the frequency of diarrhoea and mortality in early-weaned piglets to almost zero as compared to a control group not receiving egg yolk feed supplementation (Marquardt et al., 1999 and Owusu-Asiedu et al., 2002). On the other hand, other studies failed to demonstrate any effect on experimental E. coli induced diarrhoea incidence after feeding IgY with specificity against the challenge strain (Owusu-Asiedu et al., 2003a and Owusu-Asiedu et al., 2003b) and a field trial on the efficacy of anti-ETEC IgY did not show any effect on diarrhoea and mortality (Chernysheva et al., 2003).

334 In summary, there are clear indications that orally administered immunoglobulins can
335 aid piglets in handling enteric infections, both when used prophylactically and
336 therapeutically, however dose and timing need to be optimized carefully.

337

338 4.2. Cows

339 Bovine colostrum and milk contains IgG antibodies against many bacteria and yeast
340 (Kelly, 2003 and McConnell et al., 2001), and as is the case with piglets, calves are born
341 agammaglobulinemic and thus are highly dependent on efficient enteral uptake of
342 maternal IgG from colostrum in which IgG is the dominating protein at around 70 mg/ml
343 (Matte et al., 1982). However, up to 40% of new-born calves suffer from 'Failure of
344 Passive Transfer' (FPT), defined as failure to attain a serum concentration of IgG of at
345 least 10 g/L within 24–28 h after birth (Godden, 2008 and Weaver et al., 2000). Poor
346 quality colostrum (low IgG concentration) and inadequate enteral uptake of IgG are the
347 main causes of FPT (Godden, 2008 and Quigley, 2002). Calves suffering from FPT show a
348 reduced average daily weight gain and also have an increased risk of mortality within the
349 first 3 months of life (Robison et al., 1988 and Wittum and Perino, 1995). In order to
350 prevent FPT, colostrum replacer may be given to the calf just after birth, and several
351 currently marketed products for ruminants apply the passive immunisation principle
352 (Table 4) for helping new-born calves achieve adequate concentrations of circulating
353 immunoglobulins within the first 24 h after birth. E.g. colostrum replacers contain IgG
354 purified from colostrum or plasma in addition to other proteins, fat, vitamins and
355 minerals and provide 100–150 g IgG per 1.5–2 l dose (Jones and Heinrichs, 2005) and
356 colostrum replacers can thus prevent FPT.

357 In an experimental setting, Sherman et al. administered ascites fluid containing
358 monoclonal antibodies against K99 bacterial antigen orally to calves before oral
359 challenge with ETEC O9:K30:K99:F34; 82% of the untreated control calves died in
360 comparison to only 29% of the passively immunised calves (Sherman et al., 1983). This
361 demonstrates proof-of-principle for passive immunisation mediated protection against
362 this E. coli infection; however monoclonal antibodies are not generally available or
363 applicable for passive immunisation of production animals as they are prohibitively
364 expensive. They may have interest as drugs for treating and/or preventing infections in
365 very high price animals, though (thoroughbred and dressage horses, koi carps,—see
366 below). On the other hand, avian immunoglobulin (IgY, see below), in the form of the
367 water-soluble fraction of yolk from eggs of immunised birds has been demonstrated to
368 efficiently reduce ETEC infection in calves as well as in pigs and rabbits (reviewed in (
369 Chalghoumi et al., 2009)), and to provide protection against rotavirus induced diarrhoea
370 in new-born calves (Sarker et al., 2007 and Vega et al., 2011) by the enteral route. Also,
371 a number of IgY based calf feed supplements are commercially available (see Table 4).

372

373 4.3. Sheep

374 Infection with enteropathogenic *Escherichia coli* (EPEC) and *Salmonella enterica*
375 Typhimurium is common in lambs. Passive immunity obtained by transfer of maternal
376 antibodies in colostrum from ewes vaccinated with extracts of K99 pili from EPEC and
377 with live attenuated *Salmonella*, respectively has been demonstrated in lambs (Altmann
378 and Mukkur, 1983 and Mukkur et al., 1998). Lactogenic immunity against enteric
379 infections with the tapeworm *Taenis ovis* can also be achieved by vaccination of ewes
380 against the larvae (Rickard et al., 1977). Commercial products using similar maternal

381 vaccination approaches, vaccinating ewes three to four weeks before lambing are
382 available for protection against *Clostridium perfringens* types C and D infections,
383 lockjaw, lamb dysentery, pulpy kidney, and pasteurellosis (see Table 3). Several of these
384 vaccines can be administered for active immunisation for the offspring as well when the
385 initial, passively mediated protection has waned. Products for direct administration of
386 immunoglobulins for providing passive immunity in sheep against especially Clostridial
387 diseases, but also Tetanus, are listed in Table 4. Collectively, licensed products are
388 typically combination products, targeting a number of different diseases at the same
389 time, increasing cost effectiveness of the invention.

390 4.4. Horses

391 Just like ruminant neonates, foals acquire immunoglobulins from the dam's colostrum
392 by enteric uptake during a limited 'open gut' period just after birth as for example
393 illustrated by passive transfer of immunity against West Nile Virus and rotavirus from
394 dam to foal (Sheoran et al., 2000 and Wilkins et al., 2006), and indeed several licensed
395 vaccines for horses are available (Wilson, 1999) providing maternal passive immunity for
396 foals against many diseases (see Table 3). The foal are usually re-vaccinated four months
397 after parturition (Wilson, 1999). FPT can also occur in foals with adverse consequences
398 on infections rates, disease and mortality (McGuire et al., 1977). It is well established in
399 horses to use plasma transfusion as well as colostrum supplementation in foals to
400 overcome FPT (Nath et al., 2010), and other immunodeficiency diseases (Crisman and
401 Scarratt, 2008 and Tennent-Brown, 2011) (also see Table 4).

402

403 4.5. Poultry

404 Young chicks have an increased susceptibility to pathogens during the first few weeks
405 after hatching, since their immune system is not fully developed and as maternal
406 immunity is insufficient in providing full protection against certain pathogens. Passive
407 immunity has been investigated extensively in poultry (see Table 5), and a number of
408 studies provide positive indications that passive immunisation by the enteral route can
409 be used to prevent and even treat infectious diseases in poultry. The main avian
410 immunoglobulin isotype is IgY and when hatching, the majority of circulating
411 immunoglobulin is constituted by maternal IgY, while in the alimentary tract of the
412 chicken maternal IgA and IgM dominate (Hamal et al., 2006). IgY is functionally similar to
413 mammalian IgG however has four constant domains and no hinge region (reviewed in
414 (Kovacs-Nolan and Mine, 2012)). IgY is transferred from the dam to the yolk of the
415 developing egg through the ovarian follicular epithelium (Morrison et al., 2002 and Tesar
416 et al., 2008) while avian IgA and IgM are mainly found in the egg white (albumen)
417 transferred in the oviduct through the mucosal secretion (Rose et al., 1974). The amount
418 of IgY transferred to the progeny from the dam is proportional to the IgY serum
419 concentration in the dam; at day 3 the circulatory IgY concentration of the progeny is
420 approximately 30% of that of the dam (Hamal et al., 2006). The level of protection
421 provided by maternally derived IgY varies in different disease models (Table 5, Maternal
422 Protection); in some cases, even though pathogen-reactive IgY was present in both yolk
423 and serum of the hatchling it was still susceptible to experimental infection (Glavits et
424 al., 1991, Le Roy et al., 1995 and Lin and Kleven, 1984). On the other hand eight out of
425 ten studies on immunoglobulin transfer in poultry (Table 5, passive transfer) show that
426 antibodies induced by active immunisation of adult birds and then given in the form of
427 antiserum to newly hatched birds protected the recipient birds when challenged by
428 infection.

Also, a number of studies provide positive indications that passive immunisation by the enteral route; using hyper-immune IgY prevented and even treated infectious diseases in poultry (see Table 5, egg yolk immunoglobulins). The two studies that showed no protection against the pathogenic challenge by passive transfer (Table 5, passive transfer) indicate that protection against infections by antibodies may, as in other species is insufficient against certain avian pathogens such as *Histomonas meleagridis* and Avian metapneumovirus. In addition, and in contrast to neonates and young offspring of mammals the newly hatched bird does not have natural access to maternal immunoglobulin.

4.6. Fish

Similar to poultry natural passive immunity is provided to fish embryos by transfer of maternal antibodies to the embryos' yolk sack (Swain et al., 2006). The main circulating form of immunoglobulin in fish is tetrameric IgM (Rauta et al., 2012 and Salinas et al., 2011), and monomeric IgT seems to constitute the equivalent of mammalian IgA as secretory immunoglobulin associated with mucosal surfaces in fish (Salinas, 2015). Passive immunisation with immunoglobulins from other animal classes has been investigated in various infection models in fish (see Table 6). For example, complete protection of Channel catfish (*Ictalurus punctatus*) against the freshwater protozoan parasite *Ichthyophthirius multifiliis* using murine monoclonal immunoglobulins injected intraperitoneally was reported in the study by (Lin et al., 1996) and correlated with circulating murine monoclonal antibody titres against the parasite. As noted below, however, high-value antibodies such as monoclonal antibodies will probably be too expensive to find their way into use in low-cost production animals such as fish.

453 In other studies on passive transfer of immunity in catfish (Pasnik et al., 2011 and Shelby
454 et al., 2007), Nile tilapia (*Oreochromis niloticus*) (Pasnik et al., 2006), and Pacific herring
455 (*Clupea pallasii*) (Hershberger et al., 2011) only partial protection was achieved by
456 intraperitoneal administration of fish antiserum/plasma against challenge infections
457 with a range of bacterial and viral pathogens. In other studies passive transfer of
458 immunoglobulin to *Oncorhynchus mykiss* (rainbow trout), failed to provide protection
459 by injection in naïve trout, receiving serum from immune donor trout, against both
460 *Yersenia ruckeri* (Raida and Buchmann, 2008) and the parasite *Gyrodactylus derjavini* (
461 Lindenstrom and Buchmann, 2000). This indicates that in order to achieve protection
462 against these pathogens in teleost fish humoral immunity needs to be supplemented by
463 other types of immunity e.g. cell mediated immunity.

464 Oral administration of pathogen-specific IgY to fish has also been investigated.
465 Protection against Paracolo Disease and Vibriosis was obtained in Japanese eels
466 (Gutierrez et al., 1993) and in *Plecoglossus altivelis* (Ayu) (Li et al., 2014), respectively by
467 oral administration of purified IgY prophylactically in models of these two diseases. On
468 the other hand, studies in *Oncorhynchus mykiss* (rainbow trout) provided orally with
469 pathogen-specific IgY in the form of the water-soluble fraction of egg yolk formulated as
470 pellets did not demonstrate full protection against disease in models for Vibriosis and *Y.*
471 *ruckeri* infections (Arasteh et al., 2004 and Lee et al., 2000). However, full protection
472 was acquired if the *Y. ruckeri*-specific IgY was provided parenterally (egg yolk)
473 intraperitoneally (Lee et al., 2000), in contrast to the failure of whole antiserum from
474 immune donor fishes to provide protection in the same infection model (see above,
475 (Raida and Buchmann, 2008)). Highly priced ornamental fish (Koi carps) have also been
476 successfully treated with immunoglobulins. Thus, two Nishiki carps diagnosed with a
477 mixed *Aeromonas salmonicida* and *A. hydrophila* infection were successfully treated by

478 intramuscular injection with goat antiserum raised against these pathogens three times
479 over three weeks, clearing the infection (Prof. Sasaki Takeji, personal communication),
480 and it was recently published that simply immersing Koi carps in anti—*A. salmonicida* IgY
481 containing rearing water at 12.5 µg/ml protected them against skin ulcers and mortality
482 caused by subsequent exposure to this bacterium (Gan et al., 2015), probably by coating
483 the skin of the fish with the IgY antibodies. The fish IgA equivalent IgT could be
484 speculated to be useful for protecting mucosal surfaces and maybe the skin of fish,
485 however no such applications of IgT seem to be reported.

486 The use of IgY for treating other marine animals has also been studied: In a model for
487 *Vibrio alginolyticus* infection of shellfish *Haliotis diversicolor supertexta* (small abalone),
488 *Vibrio alginolyticus*-specific IgY was provided orally and increased survival from 0% to
489 more than 65% after challenge (Wu et al., 2011). *Metapenaeus ensis* (greasyback
490 shrimps) challenged with White spot syndrome virus had 73% and 33% survival, after
491 subsequent passive immunisation (IgY) and active immunisation, respectively (Lu et al.,
492 2008).

493 In general, it appears that immunity against infectious pathogens in fish can be passively
494 transferred by parenteral routes (intraperitoneally in most cases) whereas protection by
495 feeding specific immunoglobulins, being much more attractive from a practical point of
496 view, seems to be more challenging. This may be due to the presence of other easily
497 accessible entry points for infectious agent in fish, such as the gills and the fact that the
498 whole body of the fish is constantly challenged.

499

500

501 **5. Immunoglobulin sources**

502 In contrast to human medicine, the implementation of passive immunisation strategies
503 for prevention and treatment of infectious diseases in production animals like pigs, fish,
504 poultry and dairy cattle is massively dependent on the large scale availability of low cost,
505 highly efficient immunoglobulin products. That is, the immunoglobulin product needs to
506 be available to the farmer at a price that can compete with existing solutions including
507 antibiotics and vaccines (see above). In addition, ease of use and broad applicability are
508 pivotal, as are consistent quality, reliable high volume supplies and compatibility with
509 existing vaccine and diagnostic management schemes. Conventional methods for
510 producing antibodies, such as rodent- and/or cell culture derived poly- and monoclonal
511 antibodies, as used for laboratory, biotechnology and clinical and diagnostic uses in
512 humans and high value animals, are generally less useful for production of large
513 amounts of low cost immunoglobulin. This is also the case for phage-derived, and/or
514 engineered and/or recombinantly expressed immunoglobulins. Below, a number of
515 examples on alternative low cost readily available sources of immunoglobulins enabling
516 the general use of passive immunisation strategies in production animals are described.

517

518 **5.1. Blood plasma**

519 Spray-dried blood plasma (SDP) contains a high concentration of immunoglobulins and is
520 widely used as a feed additive to promote health and growth, especially in the pig
521 production (see Table S1). Documented effects in pigs include increased daily weight
522 gain, improved intestinal health and morphology and improved resistance towards
523 various pathogens (e.g. F4+ ETEC and PCV2) (see Supplementary Table 1) (Bhandari et
524 al., 2008, Hunt et al., 2002, Niewold et al., 2007, Perez-Bosque et al., 2006, Pierce et al.,

2005 and Quigley and Drew, 2000). It has also been demonstrated in pigs that SDP can protect against experimentally established *E. coli* colonisation using large amounts of SDP in just weaned pigs, significantly decreasing shedding of the challenge *E. coli* strain (Nollet et al., 1999). Approximately 20% of SDP dry matter is constituted by immunoglobulin (Pierce et al., 2005 and Quigley and Drew, 2000) and it is generally accepted that the beneficial effects of SDP is due to its copious immunoglobulin content. For example, in a study on the effect of different SDP fractions on the performance of early weaned pigs Pierce et al. (2005) demonstrated that the growth promoting effect of SDP resided in the immunoglobulin rich fraction (Pierce et al., 2005). Also, hyperimmune SDP from pigs vaccinated against F4+ ETEC more efficiently reduced shedding of F4+ ETEC in an experimental model of PWD than SDP from non-immunised animals (Niewold et al., 2007). As methods are now in place to efficiently purify immunoglobulin from slaughterhouse pig plasma by very cost-efficient methods (Lihme et al., 2010) it would be attractive to use the purified immunoglobulin fraction itself instead of SDP, and the anti-bacterial effect in experimentally challenged weaning piglets of such a purified immunoglobulin fraction purified in bulk from slaughterhouse blood was demonstrated recently by us (Hedegaard et al., 2016). The slaughterhouse pig plasma was shown to contain 'natural' antibody activity against both *E. coli* and *Salmonella enterica* spp (Hedegaard et al., 2016). Unfractionated blood products, such as SPD may harbour viral pathogens. For example, PEDV has been suggested to be present in porcine SDP (Pasick et al., 2014) although the heat treatment which is part of the spray-drying process may partly inactivate it (Gerber et al., 2014). Also, porcine parvovirus in liquid plasma has been shown to be inactivated by ultraviolet light irradiation (Polo et al., 2015). Anyhow, purification of immunoglobulin has the added benefit of allowing the removal of blood

549 borne pathogens, including viruses, such as PCV2 and porcine epidemic diarrhoea virus
550 (PEDV).

551

552 5.2. Egg yolk immunoglobulins

553 A single chicken egg contains between 100 and 250 mg IgY (Schade et al., 2005),
554 corresponding to an annual production per egg-laying hen of 20–50 g IgY (Carlander et
555 al., 2000 and Michael et al., 2010). IgY with specific binding activity can be obtained by
556 vaccination of egg-laying hens which will then deliver eggs with high antibody titres
557 against the target antigen (Kovacs-Nolan and Mine, 2012). Such IgY antibodies have
558 shown potential for treating/preventing diseases in both humans and animals (reviewed
559 in (Chalghoumi et al., 2009, Diraviyam et al., 2014 and Kovacs-Nolan and Mine, 2012),
560 also see above). Notably, IgY does not bind mammalian complement factors and Fc-
561 receptors making its use in mammals relatively uncomplicated (Inoue et al., 2015 and
562 Larsson et al., 1991). As expected, if IgY was provided parenterally to mammals a host
563 immune response towards IgY was observed (Diaz et al., 2014). However, such problems
564 have not been reported when administering IgY enterally (Michael et al., 2010).

565

566 As IgY is generally obtained from high-value human food items (eggs) from hens
567 specifically immunised against the pathogen in question this approach is per se more
568 costly than the use of immunoglobulin obtained from otherwise largely untapped
569 slaughterhouse waste products such as blood. On the other hand, IgY could potentially
570 also be purified from waste blood from broiler slaughterhouses presumably harbouring
571 reactivity against common infectious pathogens such as *Campylobacter* spp.

572

573 5.3. Milk and whey

574 As discussed extensively above colostrum and milk provide natural oro-gastric
575 protection against enteric infection in suckling off-spring. The major immunoglobulin
576 type in bovine milk and colostrum is IgG (0.5–1 mg/ml and 60–70 mg/ml, respectively)
577 (El-Loly, 2007 and Hurley and Theil, 2011). Precipitating casein from milk, as done in
578 cheese manufacturing, removes the bulk of protein from the milk, leaving the by-
579 product whey, containing around 0.5 mg/ml IgG, constituting approx. 10% of the protein
580 fraction (Siso, 1996). In cattle, a marketed whey-product (Colostrx) is claimed to protect
581 similarly to colostrum against ETEC in a *E. coli* K99-challenge model (Harman et al.,
582 1991). Although whey is claimed to have a range of dietary benefits in humans (
583 Marshall, 2004 and Patel, 2015) and pigs (Vanavichial, 1998), and it is a cheaper source
584 of immunoglobulins than milk, it however does not seem that whey is used to any
585 discernible degree for production of purified immunoglobulin preparations. This may be
586 due to the relatively low concentration of IgG in whey (<1 mg/ml) necessitating large
587 volumes to be handled during purification thereby compromising economic feasibility
588 compared to e.g. blood serum (containing around 10 mg/ml).

589

590 6. Challenges and perspectives

591 Intensive animal production systems generally face challenges in the shape of infections
592 compromising productivity, economy and animal welfare, and causing extensive use of
593 antibiotics. Active immunisation (vaccination) is a very useful alternative and
594 supplement to antibiotics for protecting against infectious pathogens as it can be used

595 to target different types of pathogens (bacteria, viruses, parasites) and as problems of
596 microbial resistance is rarely a problem. However vaccines come with their own set of
597 challenges, including their cost, and lack of efficiency in very young animals with a less
598 developed immune system, with enteric infections and with multifactorial infectious
599 disease, all of which characterize some of the most common infection related diseases
600 in production animals. This among others include weaning diarrhoea and neonatal
601 diarrhoea in pigs, diarrhoea in young calves, and a host of bacterial infections in fish fry
602 as well as the more specialized example of skin infections in high price Koi carps
603 especially associated with transport and co-mingling stress. As described in this review
604 the passive immunisation principle lends itself to meet the specific need for efficient,
605 inexpensive and non-antibiotics based intervention against these types of disease
606 problems. Numerous examples in all of the common production animals on the
607 efficiency of administered antibodies to combat or prevent infections are found in the
608 scientific literature (see above), underlining the fact that immunoglobulins, administered
609 in numerous ways and not very dependent on their source can provide short term
610 'traceless' protection against infection.

611 However, passive transfer of immunity at large scale in huge animal production facilities
612 is not always feasible and while the use of passive immunisation with immunoglobulins
613 for specific purposes like e.g. oedema disease in pigs is well-known (Johansen et al.,
614 2000), as is the principle of maternal vaccination, immunizing the offspring through a
615 natural passive immunisation process (Oanh et al., 2012), the general application of the
616 principle for the broad group of production related diseases mentioned above is
617 critically dependent upon the large-scale availability of low cost immunoglobulins e.g.
618 for supplementing the feed with immunoglobulins during challenging periods in the
619 animals' lifetime. Although a range of advanced methods for producing

immunoglobulins including monoclonal antibody protocols and recombinant antibody expression exist, such types of immunoglobulins are not expected to be prime candidates for large scale use in intensive animal production systems. Also, in practical terms easy administration of immunoglobulins is a must. For example, instead of injecting all fry in a fish production unit it would be much more practical to provide antibodies in the fry feed. Another example is the administration of colostrum feed supplements in which antibodies derived from the dam provide protection against infectious agents in the suckling offspring (see Table 4), and the provision of immunoglobulin-containing egg yolk powder as a feed supplement to reduce enteric infections e.g. in weaner piglets.

7. Conclusion

With the availability of efficient large scale methods for production of purified immunoglobulins from natural sources with certified absence of pathogenic agents the use of passive immunisation for controlling production related infectious disease problems in intensive animal production systems is likely to become relevant and feasible in the near future. In addition to offering a real and broadly applicable alternative to antibiotics with no anticipated resistance development problems, this will also allow the exploitation of largely untapped, low value side streams in the animal production sector, such as slaughterhouse blood and whey from cheese production.

Conflict of interest: None.

643 **Authors' contributions**

644 pH conceived the idea. CJH compiled the information and drafted the paper including
645 the figure and tables. pH critically reviewed and revised the paper and together with CJH
646 drafted the final version. Both authors agreed to the final version of the manuscript.

647

648 **Acknowledgement**

649 The project was supported by Green Development and Demonstration Programme
650 (Ministry of Food, Agriculture and Fisheries, The Danish AgriFish Agency, Journal
651 number: 34009-12-0471). The funder provided support in the form of salaries for the
652 author CJH, but did not have any additional role in the study design, data collection and
653 analysis, decision to publish, or preparation of the manuscript.

654

655 **Appendix A. Supplementary data**

656 The following are Supplementary data to this article:

657 Unlabelled electronic file

658

659

660

661

662

663 **References**

664 K. Altmann, T.K. Mukkur

665 Passive immunisation of neonatal lambs against infection with enteropathogenic

666 Escherichia coli via colostrum of ewes immunised with crude and purified K99 pili

667 Res. Vet. Sci., 35 (1983), pp. 234–239

668

669 N. Arasteh, A.H. Aminirissehei, A. Yousif, L.J. Albright, T.D. Durance

670 Passive immunization of rainbow trout (*Oncorhynchus mykiss*) with chicken egg yolk

671 immunoglobulins (IgY)

672 Aquaculture, 231 (2004), pp. 23–36

673

674 P. Balan, K.S. Han, V.S. Dukkupati, P.J. Moughan

675 Recovery of intact IgG in the gastrointestinal tract of the growing rat following ingestion

676 of an ovine serum immunoglobulin

677 J. Anim. Physiol. Anim. Nutr., 98 (2014), pp. 209–214

678

679 T.K. Barman, V.D. Sharma, S. Kumar

680 Protective efficacy of maternal antibodies induced by Salmonella toxoid (vaccine)

681 Indian J. Exp. Biol., 43 (2005), pp. 163–166

682

683 M.D. Barton

684 Antibiotics use in animals feed and its impact on human health

685 Nutr. Res. Rev., 13 (2000), pp. 279–299

686

687 D. Baxter

688 Active and passive immunity vaccine types, excipients and licensing

689 Occup. Med. (Lond.), 57 (2007), pp. 552–556

690

691 L.A. Bester, S.Y. Essack

692 Observational study of the prevalence and antibiotic resistance of *Campylobacter* spp.

693 from different poultry production systems in KwaZulu-Natal, South Africa

694 J. Food Prot., 75 (2012), pp. 154–159

695

696 S.K. Bhandari, B. Xu, C.M. Nyachoti, D.W. Giesting, D.O. Krause

697 Evaluation of alternatives to antibiotics using an *Escherichia coli* K88+ model of piglet

698 diarrhea: effects on gut microbial ecology

699 J. Anim. Sci., 86 (2008), pp. 836–847

700

701 N. Bleyen, E. Ons, M. De Gussem, B. Goddeeris

702 Passive immunization against *Histomonas meleagridis* does not protect turkeys from an
703 experimental infection

704 *Avian Pathol.*, 38 (2009), pp. 71–76

705

706 F.W. Brambell

707 The transmission of immunity from mother to young and the catabolism of
708 immunoglobulins

709 *Lancet*, 2 (1966), pp. 1087–1093

710

711 P. Brandtzaeg

712 The mucosal immune system and its integration with the mammary glands

713 *J. Pediatr.*, 156 (2010), pp. S8–15

714

715 Antibiotic Resistance Threats in the United States

716 Center of Disease Control (2013)

717

718 A. Calmette

719 The treatment of animals poisoned with snake venom by the injection of antivenomous
720 serum

721 Br. Med. J., 2 (1896), pp. 399–400

722

723 D. Carlander, H. Kollberg, P.E. Wejaker, A. Larsson

724 Peroral immunotherapy with yolk antibodies for the prevention and treatment of
725 enteric infections

726 Immunol. Res., 21 (2000), pp. 1–6

727

728 J. Cervenak, I. Kacskovics

729 The neonatal Fc receptor plays a crucial role in the metabolism of IgG in livestock
730 animals

731 Vet. Immunol. Immunopathol., 128 (2009), pp. 171–177

732

733 C. Chae

734 Commercial porcine circovirus type 2 vaccines: efficacy and clinical application

735 Vet. J., 194 (2012), pp. 151–157

736

737 R. Chalghoumi, Y. Beckers, D. Portetelle, A. Thewis

738 Hen egg yolk antibodies (IgY), production and use for passive immunization against
739 bacterial enteric infections in chicken: a review
740 Biotechnol. Agron. Soc., 13 (2009), pp. 295–308
741
742 L.V. Chernysheva, R.M. Friendship, C.L. Gyles, C.E. Dewey
743 Field trial assessment of the efficacy of specific egg-yolk antibody product for control of
744 postweaning E. coli diarrhea
745 Veterinary therapeutics: research in applied veterinary medicine, 4 (2003), pp. 279–284
746
747 D.K. Combs, J.H. Crabb, A.N. Bringe, F.E. Ruch, J.W. Lopez
748 Protection of neonatal calves against K99-E-Coli and Coronavirus using a colostrum-
749 derived immunoglobulin in preparation
750 Agri-Practice, 14 (1993), pp. 13–16.
751
752
753
754 S. Corbeil, S.E. LaPatra, E.D. Anderson, J. Jones, B. Vincent, Y.L. Hsu, G. Kurath
755 Evaluation of the protective immunogenicity of the N, P, M, NV and G proteins of
756 infectious hematopoietic necrosis virus in rainbow trout *Oncorhynchus mykiss* using
757 DNA vaccines

758 Dis. Aquat. Organ., 39 (1999), pp. 29–36

759

760 M.V. Crisman, W.K. Scarratt

761 Immunodeficiency disorders in horses

762 Vet. Clin. North Am. Equine Pract., 24 (2008), pp. 299–310 vi

763

764 J. Curtis, F.J. Bourne

765 Half-lives of immunoglobulins IgG, IgA and IgM in the serum of new-born pigs

766 Immunology, 24 (1973), pp. 147–155

767

768 M. Danielsen, L.J. Pedersen, E. Bendixen

769 An in vivo characterization of colostrum protein uptake in porcine gut during early

770 lactation

771 J. Proteomics, 74 (2011), pp. 101–109

772

773 G.P. Davidson, P.B. Whyte, E. Daniels, K. Franklin, H. Nunan, P.I. McCloud, A.G. Moore,

774 D.J. Moore

775 Passive immunisation of children with bovine colostrum containing antibodies to human

776 rotavirus

777 Lancet, 2 (1989), pp. 709–712

778

779 M.E. de Kraker, P.G. Davey, H. Grundmann, B.s. group

780 Mortality and hospital stay associated with resistant *Staphylococcus aureus* and

781 *Escherichia coli* bacteremia: estimating the burden of antibiotic resistance in Europe

782 PLoS Med., 8 (2011), p. e1001104

783

784 N. De Briyne, J. Atkinson, L. Pokludova, S.P. Borriello

785 Antibiotics used most commonly to treat animals in Europe

786 Vet. Rec., 175 (2014), p. 325

787

788 P. Deprez, C. Van den Hende, E. Muylle, W. Oyaert

789 The influence of the administration of sow's milk on the post-weaning excretion of

790 hemolytic *E. coli* in the pig

791 Vet. Res. Commun., 10 (1986), pp. 469–478

792

793 P. Diaz, C. Malave, N. Zerpa, H. Vazquez, G. D'Suze, Y. Montero, C. Castillo, A. Alagon, C.

794 Sevcik

795 IgY pharmacokinetics in rabbits: implications for IgY use as antivenoms

796 Toxicon, 90 (2014), pp. 124–133

797

798 T. Diraviyam, B. Zhao, Y. Wang, R. Schade, A. Michael, X. Zhang

799 Effect of chicken egg yolk antibodies (IgY) against diarrhea in domesticated animals: a
800 systematic review and meta-analysis

801 PLoS One, 9 (2014), p. e97716

802

803 J.E. Dohms, Y.M. Saif, W.L. Bacon

804 Metabolism and passive transfer of immunoglobulins in the turkey hen

805 Am. J. Vet. Res., 39 (1978), pp. 1472–1481

806

807 J.E. Dohms, Y.M. Saif, W.L. Bacon

808 Studies on metabolism and concentrations of immunoglobulin G in the newly hatched
809 turkey poult

810 Am. J. Vet. Res., 39 (1978), pp. 1466–1471

811

812 C.M. Dvorak, M.P. Lilla, S.R. Baker, M.P. Murtaugh

813 Multiple routes of porcine circovirus type 2 transmission to piglets in the presence of
814 maternal immunity

815 Vet. Microbiol., 166 (2013), pp. 365–374

816

817 ECDC/EMA, 2009. The bacterial challenge: time to react. 54.

818 EMA, 2015

819 EMA

820 Coliprotec F4 E. coli O8:K87 Vaccine (live)

821 European Medicines Agency (2015)

822

823 M.M. Eibl

824 History of immunoglobulin replacement

825 Immunol. Allergy Clin. North Am., 28 (2008), pp. 737–764

826

827 M.M. El-Loly

828 Bovine milk immunoglobulins in relation to human health

829 Int. J. Dairy Sci., 2 (2007), pp. 183–195

830

831 N. Eterradosi, D. Toquin, H. Abbassi, G. Rivallan, J.P. Cotte, M. Guittet

832 Passive protection of specific pathogen free chicks against infectious bursal disease by

833 in-ovo injection of semi-purified egg-yolk antiviral immunoglobulins

834 Zentralbl Veterinarmed B, 44 (1997), pp. 371–383

835

836 J.L. Fahey, S. Sell

837 The immunoglobulins of mice. V. The metabolic (Catabolic) properties of five

838 immunoglobulin classes

839 J. Exp. Med., 122 (1965), pp. 41–58

840

841 J.M. Fairbrother, E. Nadeau, C.L. Gyles

842 Escherichia coli in postweaning diarrhea in pigs: an update on bacterial types,

843 pathogenesis, and prevention strategies

844 Anim. Health Res. Rev., 6 (2005), pp. 17–39

845

846 J.M. Fleckenstein, P.R. Hardwidge, G.P. Munson, D.A. Rasko, H. Sommerfelt, H.

847 Steinsland

848 Molecular mechanisms of enterotoxigenic Escherichia coli infection

849 Microbes Infect., 12 (2010), pp. 89–98

850

851 N.T. Foged, P. Klemm, F. Elling, S.E. Jorsal, J. Zeuthen

852 Monoclonal antibodies to K88ab, K88ac and K88ad fimbriae from enterotoxigenic
853 Escherichia coli
854 Microb. Pathog., 1 (1986), pp. 57–69
855
856 A. Foisnet, C. Farmer, C. David, H. Quesnel
857 Relationships between colostrum production by primiparous sows and sow physiology
858 around parturition
859 J. Anim. Sci., 88 (2010), pp. 1672–1683
860
861 H.L. Forrest, A. Garcia, A. Danner, J.P. Seiler, K. Friedman, R.G. Webster, J.C. Jones
862 Effect of passive immunization on immunogenicity and protective efficacy of vaccination
863 against a Mexican low-pathogenic avian H5N2 influenza virus
864 Influenza Other Respir. Viruses, 7 (2013), pp. 1194–1201
865
866 M. Fort, M. Sibila, A. Allepuz, E. Mateu, F. Roerink, J. Segales
867 Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia
868 against PCV2 isolates of different genotypes and geographic origins
869 Vaccine, 26 (2008), pp. 1063–1071
870

871 M. Fort, M. Sibila, E. Perez-Martin, M. Nofrarias, E. Mateu, J. Segales
872 One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old
873 conventional piglets elicits cell-mediated immunity and significantly reduces PCV2
874 viremia in an experimental model
875 Vaccine, 27 (2009), pp. 4031–4037
876
877 M.J. Francis, L. Black
878 Effect of the sow vaccination regimen on the decay rate of maternally derived foot-and-
879 mouth disease antibodies in piglets
880 Res. Vet. Sci., 37 (1984), pp. 72–76
881
882 M.J. Francis, L. Black
883 The effect of vaccination regimen on the transfer of foot and mouth disease antibodies
884 from the sow to her piglets
885 J. Hyg., 93 (1984), pp. 123–131
886
887 J.W. Froude, B. Stiles, T. Pelat, P. Thullier
888 Antibodies for biodefense
889 mAbs, 3 (2011), pp. 517–527

890

891 Z.F. Fu, D.J. Hampson, C.R. Wilks

892 Transfer of maternal antibody against group A rotavirus from sows to piglets and
893 serological responses following natural infection

894 Res. Vet. Sci., 48 (1990), pp. 365–373

895

896 W. Gaastra, A.M. Svennerholm

897 Colonization factors of human enterotoxigenic *Escherichia coli* (ETEC)

898 Trends Microbiol., 4 (1996), pp. 444–452

899

900 H. Gan, H. He, A. Sato, H. Hatta, M. Nakao, T. Somamoto

901 Ulcer disease prophylaxis in koi carp by bath immersion with chicken egg yolk containing
902 anti-*Aeromonas salmonicida* IgY

903 Res. Vet. Sci., 99 (2015), pp. 82–86

904

905 P.G. Garcia, V.L. Silva, C.G. Diniz

906 Occurrence and antimicrobial drug susceptibility patterns of commensal and
907 diarrheagenic *Escherichia coli* in fecal microbiota from children with and without acute
908 diarrhea

909 J. Microbiol., 49 (2011), pp. 46–52

910

911 L. Garcia-Migura, R.S. Hendriksen, L. Fraile, F.M. Aarestrup

912 Antimicrobial resistance of zoonotic and commensal bacteria in Europe: the missing link

913 between consumption and resistance in veterinary medicine

914 Vet. Microbiol., 170 (2014), pp. 1–9

915

916 P.F. Gerber, F.M. Garrocho, A.M. Lana, Z.I. Lobato

917 Fetal infections and antibody profiles in pigs naturally infected with porcine circovirus

918 type 2 (PCV2)

919 Can. J. Vet. Res., 76 (2012), pp. 38–44

920

921 P.F. Gerber, C.T. Xiao, Q. Chen, J. Zhang, P.G. Halbur, T. Opriessnig

922 The spray-drying process is sufficient to inactivate infectious porcine epidemic diarrhea

923 virus in plasma

924 Vet. Microbiol., 174 (2014), pp. 86–92

925

926 R. Glavits, F. Ratz, V. Palya, E. Molnar, M. Nemesi

927 Pathological and immunological study of goose embryos and goslings inoculated with an
928 attenuated strain of Derzsy's disease virus
929 Acta Vet. Hung., 39 (1991), pp. 39–47
930
931 S. Godden
932 Colostrum management for dairy calves
933 Vet. Clin. North Am: Food Anim. Pract., 24 (2008), pp. 19–39
934
935 A.S. Goldman
936 Human milk, leukocytes, and immunity
937 J. Pediatr., 90 (1977), pp. 167–168
938
939 G. Gomez-Verduzco, G. Tellez, A.L. Quintana, A. Isibasi, V. Ortiz-Navarrete
940 Humoral immune response in breeding hens and protective immunity provided by
941 administration of purified Salmonella Gallinarum porins
942 Poult. Sci., 89 (2010), pp. 495–500
943
944 P.D. Greenberg, J.P. Cello

945 Treatment of severe diarrhea caused by *Cryptosporidium parvum* with oral bovine
946 immunoglobulin concentrate in patients with AIDS
947 J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 13 (1996), pp. 348–354
948
949 M.A. Gutierrez, T. Miyazaki, H. Hatta, M. Kim
950 Protective properties of egg-Yolk IgY containing anti-*Edwardsiella ictaluri* antibody against
951 Paracolo disease in the Japanese eel, *Anguilla japonica* temminck and schlegel
952 J. Fish Dis., 16 (1993), pp. 113–122
953
954 C.L. Gyles
955 *Escherichia Coli* in Domestic Animals and Humans
956 CAB International, Wallingford (1994)
957
958 D.L. Haggard, J.A. Springer, R.A. Vosdingh
959 Efficacy of a single annual booster inoculation of cows with *Escherichia-Coli* bacterin for
960 preventing enteric colibacillosis in neonatal calves
961 Vet. Med. Sm. Anim. Clin., 77 (1982), pp. 1525–1527
962
963 A.N. Haines, M.F. Flajnik, L.L. Rumfelt, J.P. Wourms

964 Immunoglobulins in the eggs of the nurse shark, *Ginglymostoma cirratum*
965 Dev. Comp. Immunol., 29 (2005), pp. 417–430
966
967 K.R. Hamal, S.C. Burgess, I.Y. Pevzner, G.F. Erf
968 Maternal antibody transfer from dams to their egg yolks, egg whites, and chicks in meat
969 lines of chickens
970 Poult. Sci., 85 (2006), pp. 1364–1372
971
972 R.J. Harman, T.V. Doherty, M.J. McCloskey
973 Colostrx supplement protects against challenge with enterotoxigenic *Escherichia-Coli* in
974 neonatal dairy calves
975 Agri-Practice, 12 (1991) 41-&
976
977 C.J. Hedegaard, M.L. Strube, M.B. Hansen, B.K. Lindved, A. Lihme, M. Boye, P.M.
978 Heegaard
979 Natural pig plasma immunoglobulins have anti-bacterial effects: potential for use as
980 feed supplement for treatment of intestinal infections in pigs
981 PLoS One, 11 (2016), p. e0147373
982

983 L.E. Hernandez-Castellano, A. Arguello, A.M. Almeida, N. Castro, E. Bendixen

984 Colostrum protein uptake in neonatal lambs examined by descriptive and quantitative

985 liquid chromatography-tandem mass spectrometry

986 J. Dairy Sci., 98 (2015), pp. 135–147

987

988 P.K. Hershberger, J.L. Gregg, C.A. Grady, S.E. LaPatra, J.R. Winton

989 Passive immunization of pacific herring against viral hemorrhagic septicemia

990 J. Aquat. Anim. Health, 23 (2011), pp. 140–147

991

992 T. Hirano, C. Hom, Z. Ovary

993 Half-life of murine IgE antibodies in the mouse

994 Int. Arch. Allergy Appl. Immunol., 71 (1983), pp. 182–184

995

996 T.T.T. Hong, N.Q. Linh, B. Ogle, J.E. Lindberg

997 Survey on the prevalence of diarrhoea in pre-weaning piglets and on feeding systems as

998 contributing risk factors in smallholdings in Central Vietnam

999 Trop. Anim. Health Prod., 38 (2006), pp. 397–405

1000

1001 J. Hong, J.M. Kim, W.K. Jung, S.H. Kim, W. Bae, H.C. Koo, J. Gil, M. Kim, J. Ser, Y.H. Park

1002 Prevalence and antibiotic resistance of *Campylobacter* spp. isolated from chicken meat,
1003 pork, and beef in Korea, from 2001 to 2006

1004 J. Food Prot., 70 (2007), pp. 860–866

1005

1006 J.L. Hsu, N. Safdar

1007 Polyclonal immunoglobulins and hyperimmune globulins in prevention and management
1008 of infectious diseases

1009 Infect. Dis. Clin. North Am., 25 (2011), pp. 773–788

1010

1011 E. Hunt, Q. Fu, M.U. Armstrong, D.K. Rennix, D.W. Webster, J.A. Galanko, W. Chen, E.M.
1012 Weaver, R.A. Argenzio, J.M. Rhoads

1013 Oral bovine serum concentrate improves cryptosporidial enteritis in calves

1014 Pediatr. Res., 51 (2002), pp. 370–376

1015

1016 W.L. Hurley, P.K. Theil

1017 Perspectives on immunoglobulins in colostrum and milk

1018 Nutrients, 3 (2011), pp. 442–474

1019

1020 H. Imberechts, P. Deprez, E. Van Driessche, P. Pohl

1021 Chicken egg yolk antibodies against F18ab fimbriae of *Escherichia coli* inhibit shedding of
1022 F18 positive *E. coli* by experimentally infected pigs
1023 *Vet. Microbiol.*, 54 (1997), pp. 329–341
1024
1025 A.Y. Inoue, A. Berchieri Jr., A. Bernardino, J.B. Paiva, E.V. Sterzo
1026 Passive immunity of progeny from broiler breeders vaccinated with oil-emulsion
1027 bacterin against *Salmonella enteritidis*
1028 *Avian Dis.*, 52 (2008), pp. 567–571
1029
1030 S. Inoue, C. Park, H. Hatta
1031 Production of polyclonal rabies virus antibodies in birds
1032 C. Rupprecht, T. Nagarajan (Eds.), *Current Laboratory Techniques in Rabies Diagnosis,*
1033 *Research and Prevention*, Academic Press (Elsevier) (2015)
1034
1035 Survival and digestibility of orally-administered immunoglobulin preparations containing
1036 IgG through the gastrointestinal tract in humans
1037 *Nutr. J.*, 14 (2015)
1038
1039 M. Johansen, L.O. Andresen, L.K. Thomsen, M.E. Busch, H. Wachmann, S.E. Jorsal, C.L.
1040 Gyles

1041 Prevention of edema disease in pigs by passive immunization

1042 Can. K. Vet. Res., 64 (2000), pp. 9–14

1043

1044 C. Jones, J. Heinrichs

1045 Colostrum Supplements and Replacer Penn State

1046 (2005) <http://extension.psu.edu/animals/dairy/nutrition/calves/colostrum/das-11-180>

1047

1048 P.W. Jones, P. Collins, M.M. Aitken

1049 Passive protection of calves against experimental-Infection with Salmonella-

1050 Typhimurium

1051 Vet. Rec., 123 (1988), pp. 536–541

1052

1053 S. Kariyawasam, B.N. Wilkie, C.L. Gyles

1054 Resistance of broiler chickens to Escherichia coli respiratory tract infection induced by

1055 passively transferred egg-yolk antibodies

1056 Vet. Microbiol., 98 (2004), pp. 273–284

1057

1058 M.A. Keller, E.R. Stiehm

1059 Passive immunity in prevention and treatment of infectious diseases

1060 Clin. Microbiol. Rev., 13 (2000), pp. 602–614

1061

1062 G.S. Kelly

1063 Bovine colostrums: a review of clinical uses

1064 Altern. Med. Rev., 8 (2003), pp. 378–394

1065

1066 J. Kim, S. Mohanty, L.P. Ganesan, K. Hua, D. Jarjoura, W.L. Hayton, J.M. Robinson, C.L.

1067 Anderson

1068 FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus

1069 J. Immunol., 182 (2009), pp. 2583–2589

1070

1071

1072

1073 R.P. Kitching, J.S. Salt

1074 The interference by maternally-derived antibody with active immunization of farm

1075 animals against foot-and-mouth disease

1076 Brit. Vet. J., 151 (1995), pp. 379–389

1077

1078 J. Kovacs-Nolan, Y. Mine

1079 Egg yolk antibodies for passive immunity

1080 Ann. Rev. Food Sci. Technol., 3 (2012), pp. 163–182

1081

1082 K. Kowalczyk, J. Daiss, J. Halpern, T.F. Roth

1083 Quantitation of maternal-fetal IgG transport in the chicken

1084 Immunology, 54 (1985), pp. 755–762

1085

1086 C.S. Kristensen, N.P. Baadsgaard, N. Toft

1087 A meta-analysis comparing the effect of PCV2 vaccines on average daily weight gain and

1088 mortality rate in pigs from weaning to slaughter

1089 Prev. Vet. Med., 98 (2011), pp. 250–258

1090

1091 G. Kurath, K.A. Garver, S. Corbeil, D.G. Elliott, E.D. Anderson, S.E. LaPatra

1092 Protective immunity and lack of histopathological damage two years after DNA

1093 vaccination against infectious hematopoietic necrosis virus in trout

1094 Vaccine, 24 (2006), pp. 345–354

1095

1096 C.H. Kweon, B.J. Kwon, J.G. Lee, G.O. Kwon, Y.B. Kang

1097 Derivation of attenuated porcine epidemic diarrhea virus (PEDV) as vaccine candidate

- 1098 Vaccine, 17 (1999), pp. 2546–2553
- 1099
- 1100 B.R. LaFrentz, S.E. LaPatra, G.R. Jones, K.D. Cain
- 1101 Passive immunization of rainbow trout, *Oncorhynchus mykiss* (Walbaum), against
- 1102 *Flavobacterium psychrophilum*, the causative agent of bacterial coldwater disease and
- 1103 rainbow trout fry syndrome
- 1104 J. Fish Dis., 26 (2003), pp. 377–384
- 1105
- 1106 A. Lardinois, T. van den Berg, B. Lambrecht, M. Steensels
- 1107 A model for the transfer of passive immunity against Newcastle disease and avian
- 1108 influenza in specific pathogen free chickens
- 1109 Avian Pathol., 43 (2014), pp. 118–124
- 1110
- 1111 J.E. Larsh
- 1112 Transmission from mother to offspring of immunity against the mouse cestode,
- 1113 *Hymenolepis nana* var *fraterna*
- 1114 Am. J. Hyg., 36 (1942), pp. 187–194
- 1115
- 1116 B.L. Larson, H.L. Heary Jr., J.E. Devery

1117 Immunoglobulin production and transport by the mammary gland
1118 J. Dairy Sci., 63 (1980), pp. 665–671
1119
1120 A. Larsson, A. Karlssonparra, J. Sjoquist
1121 Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid
1122 factors
1123 Clin. Chem., 37 (1991), pp. 411–414
1124
1125 S. Le Rousic, N. Klein, S. Houghton, B. Charleston
1126 Use of colostrum from rotavirus-immunised cows as a single feed to prevent rotavirus-
1127 induced diarrhoea in calves
1128 Vet. Rec., 147 (2000), pp. 160–161
1129
1130 D. Le Roy, C. Crouzier, M. Dho-Moulin, A.S. Dumont, A. Bouchet, J.P. Lafont, A.
1131 Andremont
1132 Results of passive and active immunization directed against ferric aerobactin in
1133 experimental enterobacterial infections in mice and chickens
1134 Res. Microbiol., 146 (1995), pp. 167–174
1135

1136 S.B. Lee, Y. Mine, R.M. Stevenson

1137 Effects of hen egg yolk immunoglobulin in passive protection of rainbow trout against

1138 *Yersinia ruckeri*

1139 J. Agric. Food Chem., 48 (2000), pp. 110–115

1140

1141 S.H. Lee, H.S. Lillehoj, D.W. Park, S.I. Jang, A. Morales, D. Garcia, E. Lucio, R. Larios, G.

1142 Victoria, D. Marrufo, E.P. Lillehoj

1143 Induction of passive immunity in broiler chickens against *Eimeria acervulina* by

1144 hyperimmune egg yolk immunoglobulin Y

1145 Poult. Sci., 88 (2009), pp. 562–566

1146

1147 S.H. Lee, H.S. Lillehoj, D.W. Park, S.I. Jang, A. Morales, D. Garcia, E. Lucio, R. Larios, G.

1148 Victoria, D. Marrufo, E.P. Lillehoj

1149 Protective effect of hyperimmune egg yolk IgY antibodies against *Eimeria tenella* and

1150 *Eimeria maxima* infections

1151 Vet. Parasitol., 163 (2009), pp. 123–126

1152

1153 B. Levast, M. Berri, H.L. Wilson, F. Meurens, H. Salmon

1154 Development of gut immunoglobulin A production in piglet in response to innate and

1155 environmental factors

1156 Dev. Comp. Immunol., 44 (2014), pp. 235–244

1157

1158 C.H. Li, X.J. Lu, D.F. Li, J. Chen

1159 Passive protective effect of chicken egg yolk immunoglobulins against experimental

1160 *Vibrio anguillarum* infection in ayu (*Plecoglossus altivelis*)

1161 Fish Shellfish Immunol., 37 (2014), pp. 108–114

1162

1163 E.M. Liebler-Tenorio, G. Riedel-Caspari, J.F. Pohlenz

1164 Uptake of colostral leukocytes in the intestinal tract of newborn calves

1165 Vet. Immunol. Immunopathol., 85 (2002), pp. 33–40

1166

1167 A. Lihme, M.B. Hansen, I.V. Andersen, T. Burnouf

1168 A novel core fractionation process of human plasma by expanded bed adsorption

1169 chromatography

1170 Anal. Biochem., 399 (2010), pp. 102–109

1171

1172 M.Y. Lin, S.H. Kleven

1173 Transferred humoral immunity in chickens to *Mycoplasma gallisepticum*

1174 Avian Dis., 28 (1984), pp. 79–87

1175

1176 W.Q. Lin, K.M. Lam, W.E. Clark

1177 Active and passive immunization of ducks against duck viral enteritis

1178 Avian Dis., 28 (1984), pp. 968–973

1179

1180 T.L. Lin, T.G. Clark, H. Dickerson

1181 Passive immunization of channel catfish (*Ictalurus punctatus*) against the ciliated

1182 protozoan parasite *Ichthyophthirius multifiliis* by use of murine monoclonal antibodies

1183 Infect. Immunol., 64 (1996), pp. 4085–4090

1184

1185 T. Lindenstrom, K. Buchmann

1186 Acquired resistance in rainbow trout against *Gyrodactylus derjavini*

1187 J. Helminthol., 74 (2000), pp. 155–160

1188

1189 S. Lloyd, E.J.L. Soulsby

1190 Passive transfer of immunity to neonatal calves against metacestodes of *Taenia-Saginata*

1191 Vet. Parasitol., 2 (1976), pp. 355–362

1192

1193 N. Lorenzen, N.J. Olesen, P.E. Jorgensen

1194 Neutralization of Egtved virus pathogenicity to cell cultures and fish by monoclonal
1195 antibodies to the viral G protein
1196 J. Gen. Virol., 71 (Pt. 3) (1990), pp. 561–567
1197
1198 Y.N. Lu, J.J. Liu, L.J. Jin, X.Y. Li, Y.H. Zhen, H.Y. Xue, J.S. You, Y.P. Xu
1199 Passive protection of shrimp against white spot syndrome virus (WSSV) using specific
1200 antibody from egg yolk of chickens immunized with inactivated virus or a WSSV-DNA
1201 vaccine
1202 Fish Shellfish Immunol., 25 (2008), pp. 604–610
1203
1204 F. Madec, N. Rose, B. Grasland, R. Cariolet, A. Jestin
1205 Post-weaning multisystemic wasting syndrome and other PCV2-related problems in pigs:
1206 a 12-year experience
1207 Transbound. Emerg. Dis., 55 (2008), pp. 273–283
1208
1209 D.M. Madson, A.R. Patterson, S. Ramamoorthy, N. Pal, X.J. Meng, T. Opriessnig
1210 Effect of porcine circovirus type 2 (PCV2) vaccination of the dam on PCV2 replication in
1211 utero
1212 Clin. Vacc. Immunol: CVI, 16 (2009), pp. 830–834
1213

1214 A. Malek

1215 Role of IgG antibodies in association with placental function and immunologic diseases

1216 in human pregnancy

1217 Expert Rev. Clin. Immunol., 9 (2013), pp. 235–249

1218

1219 M.W. Malik, N. Ayub, I.Z. Qureshi

1220 Passive immunization using purified IgYs against infectious bursal disease of chickens in

1221 Pakistan

1222 J. Vet. Sci., 7 (2006), pp. 43–46

1223

1224 N. Mancini, L. Solforosi, N. Clementi, D. De Marco, M. Clementi, R. Burioni

1225 A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of

1226 influenza

1227 Antiviral Res., 92 (2011), pp. 15–26

1228

1229 R.R. Marquardt, L.Z. Jin, J.W. Kim, L. Fang, A.A. Frohlich, S.K. Baidoo

1230 Passive protective effect of egg-yolk antibodies against enterotoxigenic Escherichia coli

1231 K88+ infection in neonatal and early-weaned piglets

1232 FEMS Immunol. Med. Microbiol., 23 (1999), pp. 283–288

1233

1234 K. Marshall

1235 Therapeutic applications of whey protein

1236 *Altern. Med. Rev.*, 9 (2004), pp. 136–156

1237

1238 J.J. Matte, C.L. Girard, J.R. Seoane, G.J. Brisson

1239 Absorption of colostral immunoglobulin G in the newborn dairy calf

1240 *J. Dairy Sci.*, 65 (1982), pp. 1765–1770

1241

1242

1243 R.E. McClead, S.A. Gregory

1244 Resistance of bovine colostral anti-cholera toxin antibody to in vitro and in vivo

1245 proteolysis

1246 *Infect. Immun.*, 44 (1984), pp. 474–478

1247

1248 M.A. McConnell, G. Buchan, M.V. Borissenko, H.J.L. Brooks

1249 A comparison of IgG and IgG1 activity in an early milk concentrate from non-immunised

1250 cows and a milk from hyperimmunised animals

1251 *Food Res. Int.*, 34 (2001), pp. 255–261

1252

1253 T.C. McGuire, T.B. Crawford, A.L. Hallowell, L.E. Macomber

1254 Failure of colostral immunoglobulin transfer as an explanation for most infections and

1255 deaths of neonatal foals

1256 J. Am. Vet. Med. Assoc., 170 (1977), pp. 1302–1304

1257

1258 N.E. McKeown, T. Opriessnig, P. Thomas, D.K. Guenette, F. Elvinger, M. Fenaux, P.G.

1259 Halbur, X.J. Meng

1260 Effects of porcine circovirus type 2 (PCV2) maternal antibodies on experimental

1261 infection of piglets with PCV2

1262 Clin. Diagn. Lab. Immunol., 12 (2005), pp. 1347–1351

1263

1264

1265 V. Melkebeek, B.M. Goddeeris, E. Cox

1266 ETEC vaccination in pigs

1267 Vet. Immunol. Immunopathol., 152 (2013), pp. 37–42

1268

1269 E. Mendez Arancibia, C. Pitart, J. Ruiz, F. Marco, J. Gascon, J. Vila

1270 Evolution of antimicrobial resistance in enteroaggregative *Escherichia coli* and
1271 enterotoxigenic *Escherichia coli* causing traveller's diarrhoea
1272 J. Antimicrob. Chemother., 64 (2009), pp. 343–347
1273
1274 A. Michael, S. Meenatchisundaram, G. Parameswari, T. Subbraj, R. Selvakumaran, S.
1275 Ramalingam
1276 Chicken egg yolk antibodies (IgY) as an alternative to mammalian antibodies
1277 Ind. J. Sci. Technol., 3 (2010), pp. 468–474
1278
1279 D.R. Morgan, H.L. DuPont, B. Gonik, S. Kohl
1280 Cytotoxicity of human peripheral blood and colostral leukocytes against *Shigella* species
1281 Infect. Immun., 46 (1984), pp. 25–33
1282
1283 S.L. Morrison, M.S. Mohammed, L.A. Wims, R. Trinh, R. Etches
1284 Sequences in antibody molecules important for receptor-mediated transport into the
1285 chicken egg yolk
1286 Mol. Immunol., 38 (2002), pp. 619–625
1287
1288 T.K. Mukkur, K.H. Walker, G.H. McDowell

1289 Passive immunisation of neonatal lambs via colostrum and milk of ewes previously
1290 immunised with live attenuated *Salmonella typhimurium* protects neonatal lambs from
1291 experimental salmonellosis
1292 *Comp. Immunol. Microbiol. Infect. Dis.*, 21 (1998), pp. 327–336
1293
1294 J.M. Murphy, J.V. Hagey, M. Chigerwe
1295 Comparison of serum immunoglobulin G half-life in dairy calves fed colostrum,
1296 colostrum replacer or administered with intravenous bovine plasma
1297 *Vet. Immunol. Immunopathol.*, 158 (2014), pp. 233–237
1298
1299 B. Nagy
1300 Vaccination of cows with a K99 extract to protect newborn calves against experimental
1301 enterotoxigenic *Escherichia coli* O157 infection
1302 *Infect. Immun.*, 27 (1980), pp. 21–24
1303
1304 L.C. Nath, G.A. Anderson, C.J. Savage, A.O. McKinnon
1305 Use of stored equine colostrum for the treatment of foals perceived to be at risk for
1306 failure of transfer of passive immunity
1307 *J. Am. Vet. Med. Assoc.*, 236 (2010), pp. 1085–1090
1308

1309 N.M. Nemeth, R.A. Bowen

1310 Dynamics of passive immunity to West Nile virus in domestic chickens (*Gallus gallus*

1311 *domesticus*)

1312 *Am. J. Trop. Med. Hyg.*, 76 (2007), pp. 310–317

1313

1314 T.A. Niewold, A.J. van Dijk, P.L. Geenen, H. Roodink, R. Margry, J. van der Meulen

1315 Dietary specific antibodies in spray-dried immune plasma prevent enterotoxigenic

1316 *Escherichia coli* F4 (ETEC) post weaning diarrhoea in piglets

1317 *Vet. Microbiol.*, 124 (2007), pp. 362–369

1318

1319 H. Nollet, P. Deprez, E. Van Driessche, E. Muylle

1320 Protection of just weaned pigs against infection with F18+ *Escherichia coli* by non-

1321 immune plasma powder

1322 *Vet. Microbiol.*, 65 (1999), pp. 37–45

1323

1324 T.K. Oanh, V.K. Nguyen, H. De Greve, B.M. Goddeeris

1325 Protection of piglets against Edema disease by maternal immunization with Stx2e toxoid

1326 *Infect. Immun.*, 80 (2012), pp. 469–473

1327

1328 Y. Oh, H.W. Seo, K. Han, C. Park, C. Chae

1329 Protective effect of the maternally derived porcine circovirus type 2 (PCV2)-specific

1330 cellular immune response in piglets by dam vaccination against PCV2 challenge

1331 J. Gen. Virol., 93 (2012), pp. 1556–1562

1332

1333 T. Opriessnig, A.R. Patterson, J. Elsener, X.J. Meng, P.G. Halbur

1334 Influence of maternal antibodies on efficacy of porcine circovirus type 2 (PCV2)

1335 vaccination to protect pigs from experimental infection with PCV2

1336 Clin. Vacc. Immunol.: CVI, 15 (2008), pp. 397–401

1337

1338 A. Owusu-Asiedu, S.K. Baidoot, C.M. Nyachoti, R.R. Marquardt

1339 Response of early-weaned pigs to spray-dried porcine or animal plasma-based diets

1340 supplemented with egg-yolk antibodies against enterotoxigenic Escherichia coli

1341 J. Anim. Sci., 80 (2002), pp. 2895–2903

1342

1343 A. Owusu-Asiedu, C.M. Nyachoti, S.K. Baidoo, R.R. Marquardt, X. Yang

1344 Response of early-weaned pigs to an enterotoxigenic Escherichia coli (K88) challenge

1345 when fed diets containing spray-dried porcine plasma or pea protein isolate plus egg

1346 yolk antibody

1347 J. Anim. Sci., 81 (2003), pp. 1781–1789

1348

1349

1350 A. Owusu-Asiedu, C.M. Nyachoti, R.R. Marquardt

1351 Response of early-weaned pigs to an enterotoxigenic *Escherichia coli* (K88) challenge

1352 when fed diets containing spray-dried porcine plasma or pea protein isolate plus egg

1353 yolk antibody, zinc oxide, fumaric acid, or antibiotic

1354 *J. Anim. Sci.*, 81 (2003), pp. 1790–1798

1355

1356 P. Palmeira, C. Quinello, A.L. Silveira-Lessa, C.A. Zago, M. Carneiro-Sampaio

1357 IgG placental transfer in healthy and pathological pregnancies

1358 *Clin. Dev. Immunol.*, 2012 (2012), p. 985646

1359

1360 Parreno et al., 2004

1361 V. Parreno, C. Bejar, A. Vagnozzi, M. Barrandeguy, V. Costantini, M.I. Craig, L. Yuan, D.

1362 Hodgins, L. Saif, F. Fernandez

1363 Modulation by colostrum-acquired maternal antibodies of systemic and mucosal

1364 antibody responses to rotavirus in calves experimentally challenged with bovine

1365 rotavirus

1366 *Vet. Immunol. Immunopathol.*, 100 (2004), pp. 7–24

1367

1368 J. Pasick, Y. Berhane, D. Ojkic, G. Maxie, C. Embury-Hyatt, K. Swekla, K. Handel, J. Fairles,
1369 S. Alexandersen

1370 Investigation into the role of potentially contaminated feed as a source of the first-
1371 detected outbreaks of porcine epidemic diarrhea in Canada

1372 Transbound. Emerg. Dis., 61 (2014), pp. 397–410

1373

1374 D.J. Pasnik, J.J. Evans, P.H. Klesius

1375 Passive immunization of Nile tilapia (*Oreochromis niloticus*) provides significant
1376 protection against *Streptococcus agalactiae*

1377 Fish Shellfish Immunol., 21 (2006), pp. 365–371

1378

1379 D.J. Pasnik, J.J. Evans, P.H. Klesius

1380 Specific serum antibody responses in channel catfish (*Ictalurus punctatus*) provide
1381 limited protection against *Streptococcus ictaluri* challenge

1382 Vet. Immunol. Immunopathol., 144 (2011), pp. 144–146

1383

1384 S. Patel

1385 Emerging trends in nutraceutical applications of whey protein and its derivatives

1386 J. Food Sci. Technol., 52 (2015), pp. 6847–6858

1387

1388 A. Perez-Bosque, C. Amat, J. Polo, J.M. Campbell, J. Crenshaw, L. Russell, M. Moreto

1389 Spray-dried animal plasma prevents the effects of *Staphylococcus aureus* enterotoxin B

1390 on intestinal barrier function in weaned rats

1391 J. Nutr., 136 (2006), pp. 2838–2843

1392

1393 B.W. Petschow, R.D. Talbott

1394 Reduction in virus-neutralizing activity of a bovine colostrum immunoglobulin

1395 concentrate by gastric acid and digestive enzymes

1396 J. Pediatr. Gastroenterol. Nutr., 19 (1994), pp. 228–235

1397

1398 J.L. Pierce, G.L. Cromwell, M.D. Lindemann, L.E. Russell, E.M. Weaver

1399 Effects of spray-dried animal plasma and immunoglobulins on performance of early

1400 weaned pigs

1401 J. Anim. Sci., 83 (2005), pp. 2876–2885

1402

1403 J. Polo, C. Rodriguez, J. Rodenas, L.E. Russell, J.M. Campbell, J.D. Crenshaw, D.

1404 Torrallardona, J. Pujols

1405 Ultraviolet light (UV) inactivation of porcine parvovirus in liquid plasma and effect of UV

1406 irradiated spray dried porcine plasma on performance of weaned pigs

1407 PLoS One, 10 (2015), p. e0133008

1408

1409 F. Qadri, T.R. Bhuiyan, D.A. Sack, A.M. Svennerholm

1410 Immune responses and protection in children in developing countries induced by oral

1411 vaccines

1412 Vaccine, 31 (2013), pp. 452–460

1413

1414 X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando, J.B. Alimonti, H. Fausther-Bovendo, H.

1415 Wei, J. Aviles, E. Hiatt, A. Johnson, J. Morton, K. Swope, O. Bohorov, N. Bohorova, C.

1416 Goodman, D. Kim, M.H. Pauly, J. Velasco, J. Pettitt, G.G. Olinger, K. Whaley, B. Xu, J.E.

1417 Strong, L. Zeitlin, G.P. Kobinger

1418 Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

1419 Nature, 514 (2014), pp. 47–53

1420

1421 J.D. Quigley, M.D. Drew

1422 Effects of oral antibiotics or bovine plasma on survival, health and growth in dairy calves

1423 challenged with Escherichia coli

1424 Food Agr. Immunol., 12 (2000), pp. 311–318

1425

1426 J. Quigley

1427 Passive immunity in newborn calves

1428 Adv. Dairy Technol., 14 (2002), pp. 273–292

1429

1430 S. Rahimi, Z.M. Shiraz, T.Z. Salehi, M.A.K. Torshizi, J.L. Grimes

1431 Prevention of salmonella infection in poultry by specific egg-Derived antibody

1432 Int. J. Poult. Sci. (2007)

1433

1434 M.K. Raida, K. Buchmann

1435 Bath vaccination of rainbow trout (*Oncorhynchus mykiss* Walbaum) against *Yersinia*

1436 ruckeri: effects of temperature on protection and gene expression

1437 Vaccine, 26 (2008), pp. 1050–1062

1438

1439 P.R. Rauta, B. Nayak, S. Das

1440 Immune system and immune responses in fish and their role in comparative immunity

1441 study: a model for higher organisms

1442 Immunol. Lett., 148 (2012), pp. 23–33

1443

1444 D.L. Reynolds, A.D. Maraqa

1445 Protective immunity against Newcastle disease: the role of antibodies specific to
1446 Newcastle disease virus polypeptides
1447 Avian Dis., 44 (2000), pp. 138–144
1448
1449 D. Reynolds, S. Akinc, A. Ali
1450 Passively administered antibodies alleviate stunting syndrome in turkey poult
1451 Avian Dis., 44 (2000), pp. 439–442
1452
1453 J.H. Rhee, S.E. Lee, S.Y. Kim
1454 Mucosal vaccine adjuvants update
1455 Clin. Exp. Vacc. Res., 1 (2012), pp. 50–63
1456
1457 M.D. Rickard, E.B. Boddington, N. McQuade
1458 Vaccination of lambs against *Taenia ovis* infection using antigens collected during in vitro
1459 cultivation of larvae: passive protection via colostrum from vaccinated ewes and the
1460 duration of immunity from a single vaccination
1461 Res. Vet. Sci., 23 (1977), pp. 368–371
1462
1463 J.D. Robison, G.H. Stott, S.K. DeNise

1464 Effects of passive immunity on growth and survival in the dairy heifer

1465 J. Dairy Sci., 71 (1988), pp. 1283–1287

1466

1467 M.E. Rose, E. Orlans, N. Buttress

1468 Immunoglobulin classes in hens egg—their segregation in yolk and white

1469 Eur. J. Immunol., 4 (1974), pp. 521–523

1470

1471 D. Rubbenstroth, S. Rautenschlein

1472 Investigations on the protective role of passively transferred antibodies against avian

1473 metapneumovirus infection in turkeys

1474 Avian Pathol., 38 (2009), pp. 427–436

1475

1476 L.J. Saif, F.M. Fernandez

1477 Group A rotavirus veterinary vaccines

1478 J. Infect. Dis., 174 (Suppl. 1) (1996), pp. S98–106

1479

1480 I. Salinas, Y.A. Zhang, J.O. Sunyer

1481 Mucosal immunoglobulins and B cells of teleost fish

1482 Dev. Comp. Immunol., 35 (2011), pp. 1346–1365

1483

1484 I. Salinas

1485 The mucosal immune system of Teleost fish

1486 Biology (Basel), 4 (2015), pp. 525–539

1487

1488 H. Salmon, M. Berri, V. Gerdt, F. Meurens

1489 Humoral and cellular factors of maternal immunity in swine

1490 Dev. Comp. Immunol., 33 (2009), pp. 384–393

1491

1492 S.A. Sarker, T.H. Casswall, D. Mahalanabis, N.H. Alam, M.J. Albert, H. Brussow, G.J.

1493 Fuchs, L. Hammerstrom

1494 Successful treatment of rotavirus diarrhea in children with immunoglobulin from

1495 immunized bovine colostrum

1496 Pediatr. Infect. Dis. J., 17 (1998), pp. 1149–1154

1497

1498 S.A. Sarker, N. Pant, L.R. Juneja, L. Hammarstrom

1499 Successful treatment of rotavirus-induced diarrhoea in suckling mice with egg yolk

1500 immunoglobulin

1501 J. Health Popul. Nutr., 25 (2007), pp. 465–468

1502

1503 K. Schade, E.G. Calzado, R. Sarmiento, P.A. Chacana, J. Porankiewicz-Asplund, H.R.

1504 Terzolo

1505 Chicken egg yolk antibodies (IgY-technology): A review of progress in production and use

1506 in research and human and veterinary medicine

1507 *Atla-Altern Lab. Anim.*, 33 (2005), pp. 129–154

1508

1509 D.F. Schuijffel, P.C. van Empel, A.M. Pennings, J.P. van Putten, P.J. Nuijten

1510 Passive immunization of immune-suppressed animals: chicken antibodies protect

1511 against *Ornithobacterium rhinotracheale* infection

1512 *Vaccine*, 23 (2005), pp. 3404–3411

1513

1514 N.S. Shahid, M.C. Steinhoff, E. Roy, T. Begum, C.M. Thompson, G.R. Siber

1515 Placental and breast transfer of antibodies after maternal immunization with

1516 polysaccharide meningococcal vaccine: a randomized, controlled evaluation

1517 *Vaccine*, 20 (2002), pp. 2404–2409

1518

1519 M.I. Shahzad, K. Naeem, M. Mukhtar, A. Khanum

1520 Passive immunization against highly pathogenic Avian Influenza Virus (AIV) strain H7N3
1521 with antiserum generated from viral polypeptides protect poultry birds from lethal viral
1522 infection
1523 Virol. J., 5 (2008), p. 144
1524
1525 R.A. Shelby, C.A. Shoemaker, P.H. Klesius
1526 Passive immunization of channel catfish *Ictalurus punctatus* with anti-Flavobacterium
1527 columnare sera
1528 Dis. Aquat. Organ., 77 (2007), pp. 143–147
1529
1530 A.S. Sheoran, S.S. Karzenski, J.W. Whalen, M.V. Crisman, D.G. Powell, J.F. Timoney
1531 Prepartum equine rotavirus vaccination inducing strong specific IgG in mammary
1532 secretions
1533 Vet. Rec., 146 (2000), pp. 672–673
1534
1535 D.M. Sherman, S.D. Acres, P.L. Sadowski, J.A. Springer, B. Bray, T.J.G. Raybould, C.C.
1536 Muscoplat
1537 Protection of calves against fatal enteric colibacillosis by orally-administered Escherichia-
1538 Coli K99-specific monoclonal-antibody
1539 Infect. Immun., 42 (1983), pp. 653–658

1540

1541 I. Shibata, Y. Okuda, K. Kitajima, T. Asai

1542 Shedding of porcine circovirus into colostrum of sows

1543 J. Vet. Med. B, 53 (2006), pp. 278–280

1544

1545 W. Si, S. Yu, L. Chen, X. Wang, W. Zhang, S. Liu, G. Li

1546 Passive protection against *Salmonella enterica* serovar Enteritidis infection from

1547 maternally derived antibodies of hens vaccinated with a ghost vaccine

1548 Res. Vet. Sci., 97 (2014), pp. 191–193

1549

1550 M.I.G. Siso

1551 The biotechnological utilization of cheese whey: a review

1552 Bioresour. Technol., 57 (1996), pp. 1–11

1553

1554 N.C. Smith, M. Wallach, M. Petracca, R. Braun, J. Eckert

1555 Maternal transfer of antibodies induced by infection with *Eimeria maxima* partially

1556 protects chickens against challenge with *Eimeria tenella*

1557 Parasitology, 109 (Pt 5) (1994), pp. 551–557

1558

1559 G. Smolenski, S. Haines, F.Y. Kwan, J. Bond, V. Farr, S.R. Davis, K. Stelwagen, T.T. Wheeler
1560 Characterisation of host defence proteins in milk using a proteomic approach
1561 J. Proteome Res., 6 (2007), pp. 207–215
1562
1563 D.R. Snodgrass, L.K. Nagy, D. Sherwood, I. Campbell
1564 Passive immunity in calf diarrhea: vaccination with K99 antigen of enterotoxigenic
1565 Escherichia coli and rotavirus
1566 Infect. Immun., 37 (1982), pp. 586–591
1567
1568 V. Snoeck, N. Huyghebaert, E. Cox, A. Vermeire, S. Vancaeneghem, J.P. Remon, B.M.
1569 Goddeeris
1570 Enteric-coated pellets of F4 fimbriae for oral vaccination of suckling piglets against
1571 enterotoxigenic Escherichia coli infections
1572 Vet. Immunol. Immunopathol., 96 (2003), pp. 219–227
1573
1574 V. Snoeck, E. Cox, F. Verdonck, J.J. Joensuu, B.M. Goddeeris
1575 Influence of porcine intestinal pH and gastric digestion on antigenicity of F4 fimbriae for
1576 oral immunisation
1577 Vet. Microbiol., 98 (2004), pp. 45–53

1578

1579 P. Swain, S. Dash, J. Bal, P. Routray, P.K. Sahoo, S.K. Sahoo, S. Saurabh, S.D. Gupta, P.K.

1580 Meher

1581 Passive transfer of maternal antibodies and their existence in eggs, larvae and fry of

1582 Indian major carp, *Labeo rohita* (Ham.)

1583 *Fish Shellfish Immunol.*, 20 (2006), pp. 519–527

1584

1585 C.O. Tacket, G. Losonsky, H. Link, Y. Hoang, P. Guesry, H. Hilpert, M.M. Levine

1586 Protection by milk immunoglobulin concentrate against oral challenge with

1587 enterotoxigenic *Escherichia coli*

1588 *N. Engl. J. Med.*, 318 (1988), pp. 1240–1243

1589

1590 B. Tennent-Brown

1591 Plasma therapy in foals and adult horses

1592 *Compendium*, 33 (2011), pp. E1–4

1593

1594 D.B. Tesar, E.J. Cheung, P.J. Bjorkman

1595 The chicken yolk sac IgY receptor, a mammalian mannose receptor family member,

1596 transcytoses IgY across polarized epithelial cells

1597 Mol. Biol. Cell, 19 (2008), pp. 1587–1593

1598

1599 G.S. Traxler, E. Anderson, S.E. LaPatra, J. Richard, B. Shewmaker, G. Kurath

1600 Naked DNA vaccination of atlantic salmon *salmo salar* against IHNV

1601 Dis. Aquat. Organ., 38 (1999), pp. 183–190

1602

1603 K. Tsubokura, E. Berndtson, A. Bogstedt, B. Kaijser, M. Kim, M. Ozeki, L. Hammarstrom

1604 Oral administration of antibodies as prophylaxis and therapy in *Campylobacter jejuni*-

1605 infected chickens

1606 Clin. Exp. Immunol., 108 (1997), pp. 451–455

1607

1608 H. Tsunemitsu, M. Shimizu, T. Hirai, H. Yonemichi, T. Kudo, K. Mori, S. Onoe

1609 Protection against bovine rotaviruses in newborn calves by continuous feeding of

1610 immune colostrum

1611 Jpn. J. Vet. Sci., 51 (1989), pp. 300–308

1612

1613 S. Tuboly, S. Bernath

1614 Intestinal absorption of colostral lymphoid cells in newborn animals

1615 Adv. Exp. Med. Biol., 503 (2002), pp. 107–114

1616

1617 Y. Umino, T. Kohama, M. Kohase, A. Sugiura, H.D. Klenk, R. Rott

1618 Protective effect of antibodies to two viral envelope glycoproteins on lethal infection

1619 with Newcastle disease virus

1620 Arch. Virol, 94 (1987), pp. 97–107

1621

1622 W. Van den Broeck, E. Cox, B.M. Goddeeris

1623 Induction of immune responses in pigs following oral administration of purified F4

1624 fimbriae

1625 Vaccine, 17 (1999), pp. 2020–2029

1626

1627

1628 W. Van den Broeck, E. Cox, B.M. Goddeeris

1629 Receptor-dependent immune responses in pigs after oral immunization with F4 fimbriae

1630 Infect. Immun., 67 (1999), pp. 520–526

1631

1632 B. Vanavichial

1633 Provision of immunoglobulins to sucking piglets can enhance post-weaning growth

1634 performance

1635 Department of Animal Science, Massey University, New Zealand (1998)

1636

1637 C. Vega, M. Bok, P. Chacana, L. Saif, F. Fernandez, V. Parreno

1638 Egg yolk IgY: protection against rotavirus induced diarrhea and modulatory effect on the

1639 systemic and mucosal antibody responses in newborn calves

1640 Vet. Immunol. Immunopathol., 142 (2011), pp. 156–169

1641

1642 G. Vidarsson, G. Dekkers, T. Rispens

1643 IgG subclasses and allotypes: from structure to effector functions

1644 Front. Immunol., 5 (2014), p. 520

1645

1646 E. Vidor

1647 2007: Vaccination of newborns against hepatitis A in the presence of maternally derived

1648 antibodies

1649 J. Comp. Pathol., 137 (Suppl. 1) (2007), pp. S42–45

1650

1651 V. Viridi, A. Coddens, S. De Buck, S. Millet, B.M. Goddeeris, E. Cox, H. De Greve, A.

1652 Depicker

1653 Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic
1654 *Escherichia coli* infection

1655 Proc. Natl. Acad. Sci. U.S.A., 110 (2013), pp. 11809–11814

1656

1657 E.W. Voss Jr., W.J. Groberg Jr., J.L. Fryer

1658 Metabolism of coho salmon Ig. Catabolic rate of coho salmon tetrameric Ig in serum

1659 Mol. Immunol., 17 (1980), pp. 445–452

1660

1661 WHO, 2012. The Evolving Threat of Antimicrobial Resistance Options for Action World
1662 Health Organisation.

1663

1664 D.L. Watson

1665 Biological half-life of ovine antibody in neonatal lambs and adult sheep following passive
1666 immunization

1667 Vet. Immunol. Immunopathol., 30 (1992), pp. 221–232

1668

1669 D.M. Weaver, J.W. Tyler, D.C. VanMetre, D.E. Hostetler, G.M. Barrington

1670 Passive transfer of colostral immunoglobulins in calves

1671 J. Vet. Intern. Med., 14 (2000), pp. 569–577

1672

1673 P.A. Wilkins, A.L. Glaser, S.M. McDonnell

1674 Passive transfer of naturally acquired specific immunity against West Nile Virus to foals

1675 in a semi-feral pony herd

1676 J. Vet. Intern. Med., 20 (2006), pp. 1045–1047

1677

1678 W.D. Wilson, J.E. Mihalyi, S. Hussey, D.P. Lunn

1679 Passive transfer of maternal immunoglobulin isotype antibodies against tetanus and

1680 influenza and their effect on the response of foals to vaccination

1681 Equine Vet. J., 33 (2001), pp. 644–650

1682

1683 W.D. Wilson

1684 Vaccination programs for foals and weanlings

1685 Proceedings of the Annual Convention of the AAEP, American Association of Equine

1686 Practitioners, Albuquerque (NM) (1999), pp. 254–263

1687

1688 T.E. Wittum, L.J. Perino

1689 Passive immune status at postpartum hour 24 and long-term health and performance of

1690 calves

1691 Am. J. Vet. Res., 56 (1995), pp. 1149–1154

1692

1693 C.J. Wu, H. Wang, Y.L. Chan, T.L. Li

1694 Passive immune-protection of small abalone against *Vibrio alginolyticus* infection by

1695 anti-*Vibrio* IgY-encapsulated feed

1696 Fish Shellfish Immunol., 30 (2011), pp. 1042–1048

1697

1698 S. Ylitalo, M. Uhari, S. Rasi, J. Pudas, J. Leppaluoto

1699 Rotaviral antibodies in the treatment of acute rotaviral gastroenteritis

1700 Acta Paediatr., 87 (1998), pp. 264–267

1701

1702 H. Yokoyama, T. Hashi, K. Umeda, F.C. Icatlo Jr., M. Kuroki, Y. Ikemori, Y. Kodama

1703 Effect of oral egg antibody in experimental F18+ *Escherichia coli* infection in weaned pigs

1704 J. Vet. Intern. Med., 59 (1997), pp. 917–921

1705

1706 R.H. Yolken, G.A. Losonsky, S. Vonderfecht, F. Leister, S.B. Wee

1707 Antibody to human rotavirus in cow's milk

1708 N. Engl. J. Med., 312 (1985), pp. 605–610

1709

1710 L. Zeitlin, R.A. Cone, K.J. Whaley

1711 Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious

1712 diseases

1713 *Emerg. Infect. Dis.*, 5 (1999), pp. 54–64

1714

1715 Q. Zhang, J.K. Cundiff, S.D. Maria, R.J. McMahon, M.S. Wickham, R.M. Faulks, E.A. van

1716 Tol

1717 Differential digestion of human milk proteins in a simulated stomach model

1718 *J. Proteome Res.*, 13 (2014), pp. 1055–1064

1719

1720 M. Zhou, Q. Duan, X. Zhu, Z. Guo, Y. Li, P.R. Hardwidge, G. Zhu

1721 Both flagella and F4 fimbriae from F4ac⁺ enterotoxigenic *Escherichia coli* contribute to

1722 attachment to IPEC-J2 cells in vitro

1723 *Vet. Res.*, 44 (2013), p. 30

1724

1725 Corresponding author at: Technical University of Denmark, National Veterinary Institute,

1726 Bülowsvej 27, DK-1870 Frederiksberg C, Denmark.

1727 © 2016 Elsevier B.V. All rights reserved.

1728

1729 **Tables**

1730 **Table 1**

Immunoglobulin half-life		
Species	Half-life (days) ^a	References
Pig	14	(Curtis and Bourne, 1973)
Cow	29	(Murphy et al., 2014)
Sheep	12-24 ^b	(Watson, 1992)
Horse	27-39 ^b	(Wilson et al., 2001)
Poultry (turkey)	4-6 ^b	(Dohms et al., 1978a, b)
Fish (salmon)	2	(Voss et al., 1980)
Man	21 ^c	(Vidarsson et al., 2014)
Mouse	3-5	(Fahey and Sell, 1965)

1731

1732

1733

1734

1735

1736 ^a Pig, cow, sheep, horse, mouse and man; IgG. Poultry; IgY. Fish; tetrameric IgM.

1737 ^b Half-life changes from neonate to adult and varies between IgG subtypes.

1738 ^c Certain allotypes of IgG3 can have much shorter half-lives.

1739

1740

1741

1742

1743

Licensed ^a immunoglobulin products for human passive immunisation	
Disease/pathogen source	Immunoglobulin product
Allograft rejection	Equine or rabbit anti-thymocyte IgG
Anthrax	Monoclonal antibody (Raxibacumab and Obiltoxaximab), immune human Ig (Anthravig TM)
Black widow spider	Equine Ig
Snakebite	Scorpion
	Equine F(ab') ₂ ^b
	Rattlesnake ^c
	Ovine Fab ^b
Botulism	Type A and B
	Human Ig
	Type A-G
	Equine Ig
Chickenpox, shingles (Varicella-Zoster virus)	Immune human Ig ^d
Cytomegalovirus	Immune human Ig
Digoxin toxicity or overdose	Ovine Fab ^b
Diphtheria	Specific equine Ig
Hepatitis A, measles	Pooled human Ig
Hepatitis B	Immune human Ig
Primary Humoral Immunodeficiency, Immune Thrombocytopenic Purpura, (prevention of) allogeneic bone marrow transplantation rejection, Guillain Barré syndrome, Kawasaki disease	Pooled human IgG ^d
Rabies	Immune human Ig

Respiratory syncytial virus induced disease	Monoclonal antibody (Palivizumab)
Smallpox (Vaccinia virus)	Immune human Ig
Tetanus	Immune human Ig ^d

1745 ^a Licensed by either FDA or EMEA

1746 ^b Fab/F(ab')₂ denotes products of IgG molecules after enzymatic digestion still capable of
1747 binding to antigen in question.

1748 ^c Rattlesnake antivenom covers following species: North American snake venoms:
1749 *Crotalus atrox* (Western Diamondback rattlesnake), *Crotalus adamanteus* (Eastern
1750 Diamondback rattlesnake), *Crotalus scutulatus* (Mojave rattlesnake), and *Agkistrodon*
1751 *piscivorus* (Cottonmouth or Water Moccasin).

1752 ^d Pooled human IgG (i.e. IVIG) can also be used

1753

1754

1755

1756

1757

1758

1759

1760

1761

Licensed Products for induction of maternal immunity for passive immunisation of progeny ^a		
Product	Animal	Disease/pathogen prevention
Equine Rotavirus Vaccine	Horse	<i>Rotaviral diarrhoea</i>
Strep-Vax II ^b , Pinnacle [®] I.N.	Horse	<i>Strangles</i>
Equivac [®] 2in 1 ^b	Horse	<i>Tetanus, Strangles</i>
Botvax B	Horse	<i>Butolism</i>
Prestige [®] V + WNV ^b	Horse	<i>Eastern and Western Encephalomyelitis, Tetanus, Influenza, equine herpesvirus and West Nile virus</i>
Eryvac ^{®b}	Sheep	<i>Erysipelas polyarthrits</i>
Glanvac [®] 6 ^b	Sheep + Goat	<i>Cheesy Gland, malignant oedema, lamb dysentery, pulpy kidney, struck, tetanus, braxy,</i>
Hepatavac P Plus ^b	Sheep	<i>blackleg, black disease and clostridial metritis</i>
Bravoxin 10, Ultravac [®] 5in1 ^b	Cattle + Sheep	^c <i>Clostridium perfringens</i> type A; <i>C. perfringens</i> type B; <i>C. perfringens</i> type C; <i>C. perfringens</i> type D; <i>C. chauvoei</i> ; <i>C. novyi</i> type B; <i>C. septicum</i> ; <i>C. sordellii</i> ; <i>C. haemolyticum</i> , and <i>C. tetani</i>
BoviShot [®] PneumoGuard4	Cattle	Pneumonic Pasteurellosis
Rotagal, Rotavec,	Cattle	Scours (rota –, coronavirus and <i>E. coli</i>)

BoviShot® ROCO	Cattle	Scours (rota –, coronavirus)
NeoVac®	Swine	Scours/Colibacillosis (E. coli)
Porcilis Ery ^b	Swine	Erysipelas (<i>Erysipelothrix rhusiopathiae</i>)
Lepto-Eryvac® ^b	Swine	Erysipelas and Leptospirosis
Rhini Shield® TX4 ^b	Swine	Atrophic rhinitis, Erysipelas and Pneumonic Pasteurellosis
LitterGuard® LT-C	Swine	Enterotoxemia and Colibacillosis
ProSystem® TREC	Swine	Rotaviral diarrhoea, Transmissible gastroenteritis, Enterotoxemia and Colibacillosis
Prefarrow Strep Shield ^b	Swine	Meningitis, Septicemia and Streptococcosis
CircoVac ^b	Swine	PCVAD (Porcine circo virus type 2)
SuiShot® Aujeszkey ^b	Swine	Aujeszkey disease
SuiShot® PT-100	Swine	Porcine epidemic diarrhoea and Transmissible gastroenteritis
SuiShot® AR-DT	Swine	Pneumonic Pasteurellosis
SuiShot® Allres ^b	Swine	Glasser's disease, Enzootic Pneumonia (Mycoplasma hyopneumoniae), Pneumonic Pasteurellosis, Pleuropneumonia (Actinobacillus pleuropneumoniae), Streptococcosis, and Atrophic rhinitis
Gripovac 3	Swine	Swine influenza (H1N1, H1N2, H3N2)

1763 ^a Active vaccines intended for providing the offspring with immunity through colostrum.

1764 ^b Can be administered for active immunisation for the offspring when initial protection
1765 has waned.

1766 ^c Pathogens that cause the above-mentioned diseases

1767

1768

1769

1770

1771

1772

1773

1774

1775

1776

1777

1778

1779

1780

1781

1782

1783 **Table 4**

Licensed products for passive immunisation of ruminants, horses and pigs				
Product type	Animal	Disease prevention/targeted pathogens	Immunoglobulin type/origin	Administration (Oral/parenteral)
<i>E. coli</i> specific antibodies	Calves	Scour	Bovine colostrum IgG/IgY	Oral
Antibacterial bovine serum antibodies	Cattle Calves Sheep	<i>Arcanobacterium</i> <i>pyogenes</i> <i>E. coli</i> <i>Mannheimia</i> <i>haemolytica</i> <i>Pasteurella multocida</i> <i>Salmonella</i> Typhimurium	Bovine serum	Parenteral
<i>Clostridial</i> antitoxins	Cattle Calves Goat Sheep Swine Horses	<i>Clostridium perfringens</i> C&D <i>Clostridium Botulinum</i> C&B	Equine Ig	Parenteral (sc and iv)
Tetanus Antitoxin	Horses Cattle	Tetanus	Equine serum	Parenteral

	Sheep Swine Goats			
Anti-West Nile Virus Antibodies	Horses	West Nile Virus	Equine Ig	Parenteral
Anti-endotoxin antibodies	Horses	Septicaemia	Equine plasma from hyper- immune horses	Parenteral
Antibacterial plasma antibodies	Horses	<i>Rhodococcus equi</i> <i>E. coli</i> J-5	Equine plasma from hyper- immune horses	Parenteral
Equine plasma	Horses	Failure of Passive Transfer	Equine plasma	Both

1784

1785

1786

1787

1788

1789

1790

1791

1792

1793

1794

1795

1796

1797

1798

1799

1800 **Table 5**

Studies on passive immunisation of birds				
Immunoglobulin type	Method of delivery	Model (disease/pathogen)	Species	References
Polyclonal antibody ^a	Enteral (milk)	<i>Campylobacter jejuni</i>	Chicken	(Tsubokura et al., 1997)
Egg yolk immunoglobulins	Enteral	Avian coccidiosis	Chicken	(Lee et al., 2009a, b)
	Intramuscular	<i>Escherichia coli</i> spp.	Chicken	(Kariyawasam et al., 2004)
	Intraperitoneal	Infectious bursal disease (Birnavirus)	Chicken	(Malik et al., 2006)
	Enteral	<i>Campylobacter jejuni</i>	Chicken	(Tsubokura et al., 1997)

	Enteral	<i>Salmonella</i> Enteritidis	Chicken	(Rahimi et al., 2007)
	<i>In ovo</i>	Infectious bursal disease virus	Chicken	(Eterradossi et al., 1997)
Passive transfer ^b	Intraperitoneal	Newcastle disease	Chicken	(Lardinois et al., 2014)
	Intravenous			(Umino et al., 1987)
	Subcutaneous			(Reynolds and Maraqa, 2000)
	n/a	Avian Influenza Virus, H7N3	Chicken	(Shahzad et al., 2008)
	Intraperitoneal	Histomonosis (blackhead)	Turkey	^c (Bleyen et al., 2009)
	Subcutaneous	Stunting syndrome	Turkey	(Reynolds et al., 2000)
	Intravenous	Avian metapneumovirus	Turkey	^c (Rubbenstroth and Rautenschlein, 2009)
	Intramuscular	Duck enteritis virus	Duck	(Lin et al., 1984)
	Subcutaneous	<i>Mycoplasma</i>	Chicken	(Lin and

	Intravenous	<i>gallisepticum</i> <i>Ornithobacterium</i> <i>rhinotracheale</i>	Chicken	<u>Kleven, 1984)</u> <u>(Schuijffel et</u> <u>al., 2005)</u>
Maternal protection ^d		<i>Salmonella</i> spp.	Chicken	<u>(Barman et al.,</u> <u>2005; Gomez-</u> <u>Verduzco et</u> <u>al., 2010;</u> <u>Inoue et al.,</u> <u>2008; Si et al.,</u> <u>2014)</u>
		<i>Eimeria tenella</i>	Chicken	<u>(Smith et al.,</u> <u>1994)</u>
		Newcastle disease	Chicken	<u>(Umino et al.,</u> <u>1987)</u>
		Derzsy's disease virus	Goose	^c <u>(Glavits et</u> <u>al., 1991)</u>
		<i>Mycoplasma</i> <i>gallisepticum</i>	Chicken	^c <u>(Lin and</u> <u>Kleven, 1984)</u>
		<i>E. coli</i> MT78	Chicken	^c <u>(Le Roy et al.,</u> <u>1995)</u>
		West Nile virus	Chicken	<u>(Nemeth and</u> <u>Bowen, 2007)</u>

1801

1802 ^a Transfer/delivery of antibodies/antiserum from other species (e.g. mouse to chicken)

1803 ^b Transfer/delivery of antibodies/antiserum from same species (e.g. chicken to chicken).

1804 ^c Indication of passive immunity/protection was negative.

1805 ^d No transfer of antibodies/antisera other than from mother to egg.

1806

1807

1808

1809

1810

1811

1812

1813

1814 **Table 6**

Studies on passive immunisation of fish		
Immunoglobulin type	Model (disease/pathogen)	References
Monoclonal antibody	White spot disease (<i>Ichthyophthirius multifiliis</i>)	(Lin et al., 1996)
	Viral haemorrhagic septicaemia virus	(Lorenzen et al., 1990)
Egg yolk immunoglobulins (IgY)	<i>Vibrosis (Vibrio anguillarum)</i>	(Arasteh et al., 2004)

	Redmouth disease (<i>Yersinia ruckeri</i>)	(Lee et al., 2000)
Passive transfer (serum/plasma)	Redmouth disease (<i>Yersinia ruckeri</i>) Columnaris disease (<i>Flavobacterium columnare</i>) <i>Gyrodactylus derjavini</i> <i>Streptococcus ssp.</i> Rainbow trout fry syndrome (<i>Flavobacterium psychrophilum</i>) Viral haemorrhagic septicaemia virus	(Raida and Buchmann, 2008) (Shelby et al., 2007) (Lindenstrom and Buchmann, 2000) (Pasnik et al., 2006, 2011) (LaFrentz et al., 2003) (Corbeil et al., 1999 ; Hershberger et al., 2011 ; Kurath et al., 2006 ; Traxler et al., 1999)

1815

1816

1817

1818

1819

1820

1821

Effects of SDP^a meal supplement^d			
Animal	Disease model	Effect	References
Piglets (6-20 days post weaning)	Experimental induced diarrhoea by <i>E. coli</i>	SDP ¹ reduced disease in piglets experimentally inoculated with <i>E. coli</i> O149K91. Faecal excretion of the <i>E. coli</i> was also reduced by SDP originating from <i>E. coli</i> O149K91-immunised pigs	(Niewold et al., 2007)
Piglets (7 days post weaning)		Dietary SDP significantly reduced mortality in comparison to the control group but SDP did not provide same level of protection against the <i>E. coli</i> inoculate as a group receiving antibiotics.	(Bhandari et al., 2008)
Piglets (7 and 14 days post weaning)	Post weaning diarrhoea (PWD)	Dietary porcine SDP had a positive influence on intestinal barrier function and reduced inflammation and diarrhoea.	(Peace et al., 2011)
Piglets (14 and 28 days post weaning)	The effect of SDP on piglet growth and intestinal morphology	Piglets given SDP had improved ADG ^b for 14 and increased body weight and crypt/villus ratios at day 28 as compared to control piglets.	(Tran et al., 2014)

Piglets	Salmon hydrolysate dietary supplement over SDP	Within the first 7 days, SDP, especially in 1+1 combination with salmon hydrolysate significantly improved ADG ^b and daily feed intake	(Tucker et al., 2011)
Piglets (5 days pre-weaned)	The effect of SDP on stress (weaning and transportation)	SDP provided post-weaned piglets with increased bodyweight and decreased levels of stress markers	(Wittish et al., 2014)
Piglets (28 days post weaning)	The effect of ultraviolet light on SDP	Ultraviolet light inactivated porcine parvovirus in liquid plasma, and SPD derived from ultraviolet radiated plasma improved growth in weaner piglets.	(Polo et al., 2015)
Sows	The effect of SDP on sow productivity: piglet survival to weaning, weaning interval, last lactation day of offspring, number of piglets and weight of litter, and ADG ^b and ADFI ^c of litter.	Dietary SDP had a significant positive effect on productivity in older sows (in parity 4) as compared to younger sows.	(Früge et al., 2009)

Cattle	The effect of bovine SDP against <i>E. coli</i> infection, incl. ADG ^b .	SDP resulted in borderline significant decrease in mortality and a significant increase in ADG ^b .	(Quigley and Drew, 2000)
Broilers	The effect of SDP on chicken growth	Bovine SDP significantly increased ADG and feed intake for up to 28 days after hatching.	(Campbell et al., 2006)
Chickens (1-28 days old)		Porcine SDP had no effect on body weight after 4 weeks of feeding (in comparison with control group).	(Jamroz et al., 2011)
Chicken (1-30 days old)		Porcine SDP had a significantly positive effect on body weight after 4 weeks of feeding.	(Jamroz et al., 2012)
Isa Brown hens	The effect of SDP on egg composition	The introduction of spray-dried blood by-products did not have any beneficial effects on egg quality, yolk and mineral content.	(Orda et al., 2012)
Wistar-Lewis rats (21 days post weaning)	Experimental induced intestinal inflammation with <i>Staphylococcus aureus</i> enterotoxin B.	Dietary SDP (and Ig concentrate) attenuated intestinal inflammation.	(Perez-Bosque et al., 2006 ; Perez-Bosque et al., 2008, 2010)
Male C57BL/6 mice (19 days old)	Experimental LPS-induced pulmonary	SDP (and Ig concentrate) decreased both the adaptive and	(Maijo et al., 2012a, b)

	inflammation	innate immune response.	
<i>Sparus aurata</i> (Gilthead sea bream) fingerlings	The effect of SDP on fingerling fish growth and intestinal mucosal	SDP improved fish size, weight, and increased density of intestinal goblet cells	(<u>Gisbert et al., 2015</u>)

1823 ^a SDP = Spray-dried plasma

1824 ^b ADG = average daily growth

1825 ^c ADFI = average daily feed intake

1826 ^d Also see (Torrallardona, 2010) for more on the effects in pigs